var title_f13_55_14192="Periaerolar abscess";
var content_f13_55_14192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periareolar abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Periareolar abscess. Large incisions are not necessary for the drainage of a breast abscess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14192=[""].join("\n");
var outline_f13_55_14192=null;
var title_f13_55_14193="Erythema multiforme extrem";
var content_f13_55_14193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple typical target lesions are present on this extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14193=[""].join("\n");
var outline_f13_55_14193=null;
var title_f13_55_14194="Positioning for puncture of radiocarpal joint";
var content_f13_55_14194=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Positioning for ultrasound-guided puncture of radiocarpal joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Puncture of the dorsal radiocarpal joint under direct&nbsp;ultrasound guidance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14194=[""].join("\n");
var outline_f13_55_14194=null;
var title_f13_55_14195="Medium chain triglycerides: Pediatric drug information";
var content_f13_55_14195=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Medium chain triglycerides: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"    see \"Medium chain triglycerides: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30164?source=see_link\">",
"    see \"Medium chain triglycerides: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      MCT Oil&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      MCT Oil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Caloric Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nutritional Supplement, increase caloric content:",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be individualized to patient  caloric needs, current nutritional/fluid status, and other clinical parameters. Initial: 0.5 mL every other feeding, then advance to every feeding, then increase in increments of 0.25-0.5 mL/feeding at intervals of 2-3 days as tolerated; lower initial doses may be used depending upon caloric needs; product formulation provides 115 calories/15 mL",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"      see \"Medium chain triglycerides: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cystic fibrosis: Children and Adults: 45 mL/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Malabsorption syndromes: Adults: 15 mL 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nutritional supplement: Infants: Initial: 0.5 mL every other feeding, then advance to every feeding, then increase in increments of 0.25-0.5 mL/feeding at intervals of 2-3 days as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Seizures: Children: About 40 mL with each meal or 50% to 70% (800-1120 kcal) of total calories (1600 kcal) as the oil will induce the ketosis necessary for seizure control",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MCT Oil&reg;: 14 g/15 mL (960 mL) [gluten free; contains coconut oil; 115 cal/15 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dilute with at least an equal volume of water or mix with some other vehicle such as fruit juice (should not be cold; flavoring may be added); mixture should be sipped slowly; administer no more than 15-20 mL at any one time (up to 100 mL may be administered in divided doses in a 24-hour period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Possible GI side effects from medication can be prevented if therapy is initiated with small supplements at meals and gradually increased according  to patient's tolerance",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nutritional supplement for those who cannot digest long chain fats; malabsorption associated with disorders such as pancreatic insufficiency, bile salt deficiency, and bacterial overgrowth of the small bowel; induce ketosis as a prevention for seizures (akinetic, clonic, and petit mal)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: HDL serum levels decreased and triglycerides serum levels increased (&gt;6 months daily use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, bloating, cramping, diarrhea, nausea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to medium chain triglycerides or any component; should not be used in patients with hepatic encephalopathy due to earlier observations which report that short chain fatty acids may have a narcotic effect on the CNS and inhibit oxidative phosphorylation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic cirrhosis and complications such as portacaval shunts or encephalopathy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with cirrhosis demonstrate higher concentrations of medium chain fatty acids in the serum and CSF than normal individuals; impaired hepatic clearance of medium chain fatty acids due to parenchymal dysfunction of medium chain fatty acid oxidation, portal systemic shunt, and impaired protein binding of fatty acid enhance the passive diffusion of medium chain fatty acids into the CSF",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nutritional supplement and malabsorption: Weight gain, height, stool output",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Seizure treatment: Reduction in seizures, urine ketones",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A semisynthetic class of lipids; medium chain triglycerides (MCT) are composed of fatty acids with chain length varying from 6-12 carbon atoms; preparations contain approximately 75% octanoic (caprylic), 20% to 25% decanoic (capric), 1% hexanoic (caproic), and 1% dodecanoic (lauric) acids",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     MCT are hydrolyzed in the stomach and in the small intestine by pancreatic lipase to form medium chain fatty acids; the medium chain fatty acids are incorporated into bile salts for more rapid solubilization and entrance into the mucosal cell and into the portal venous blood; MCT can also be absorbed unchanged as a triglycerides into the mucosal cell; medium chain fatty acids presented to the liver are minimally converted to hepatic lipid and are rapidly oxidized to carbon dioxide, ketones, and acetate; the medium chain fatty acids are also esterified to long chain triglycerides",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Octanoic acid appeared in each subject by 30 minutes following ingestion; effect on seizures in children: Within 6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Up to 30% of dose can be absorbed unchanged as a triglyceride in the mucosal cell",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Almost entirely oxidized by the liver to acetyl CoA fragments and to carbon dioxide; little deposited in adipose tissue or elsewhere",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: As much as 20% of oral dose of MCT, recovered in expired CO",
"     <sub>",
"      2",
"     </sub>",
"     in 50 minutes; &lt;10% elimination of medium chain fatty acids in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30164?source=see_link\">",
"      see \"Medium chain triglycerides: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     GI symptoms may occur during the first few days of administration and then disappear; it is important to continue therapy with at least the smallest dose",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1060084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not provide any essential fatty acids; contains only saturated fats; supplementation with safflower, corn oil, or other polyunsaturated vegetable oil must be given to provide the patient with the essential fatty acids; caloric content: 8.3 calories/g; 115 calories/15 mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12576 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14195=[""].join("\n");
var outline_f13_55_14195=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191959\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191960\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060076\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675196\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060071\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191949\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191939\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060079\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060078\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191970\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060083\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060070\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060069\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060075\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060068\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060081\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060082\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060074\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060084\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12576|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=related_link\">",
"      Medium chain triglycerides: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30164?source=related_link\">",
"      Medium chain triglycerides: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_55_14196="Follicular carcinoma FNA";
var content_f13_55_14196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fine needle aspirate of the thyroid showing microfollicles and minimal follicle development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate of a thyroid nodule showing microfollicles and minimal follicle development. The specimen is cellular, and the cells are crowded, pleomorphic, and clumped. Colloid is scant. This lesion was excised and found to be an invasive follicular cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14196=[""].join("\n");
var outline_f13_55_14196=null;
var title_f13_55_14197="Botulinum toxin injection - glabellar rhytides";
var content_f13_55_14197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64007%7EDERM%2F65462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64007%7EDERM%2F65462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection for glabellar rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 155px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images of glabellar rhytides prior to botulinum toxin injection (A) and after injection (B) are shown. The patient is attempting a strong frown in both images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection sites for glabellar lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The five central injections represent the primary sites for botulinum toxin injection for glabellar lines (red). Some patients may benefit from two additional injections into the lateral orbicularis oculi muscle (white).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14197=[""].join("\n");
var outline_f13_55_14197=null;
var title_f13_55_14198="Pseudopolyps in UC BE";
var content_f13_55_14198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56793%7EGAST%2F63353%7EGAST%2F65953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56793%7EGAST%2F63353%7EGAST%2F65953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudopolyps in ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema demonstrates mucosal pseudopolyps (arrows) and a stricture arising in the descending colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Filiform polyps in chronic ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema shows fine linear polyps arising from the colon wall (arrows). These polyps are typically seen in chronic ulcerative colitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema in a patient with chronic ulcerative colitis shows a featureless colon with complete loss of folds in the sigmoid colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14198=[""].join("\n");
var outline_f13_55_14198=null;
var title_f13_55_14199="Chronic irritant contact dermatitis";
var content_f13_55_14199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50299%7EDERM%2F59959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50299%7EDERM%2F59959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ill-defined dry, scaly patches with fissuring on the finger in a patient with chronic irritant contact dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kulthanan K. Siriraj Hospital, Mahidol University, Bangkok, Thailand.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chronic irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema, fissuring, and scaling resulting from repeated exposure to irritants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14199=[""].join("\n");
var outline_f13_55_14199=null;
var title_f13_55_14200="Carnitine metabolism in renal disease and dialysis";
var content_f13_55_14200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carnitine metabolism in renal disease and dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14200/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14200/contributors\">",
"     Alan Wasserstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14200/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14200/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/55/14200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    deficiency may be a significant problem in patients with kidney disease, particularly in those undergoing maintenance dialysis. A discussion of carnitine metabolism, as well as the role of carnitine supplementation in this patient population, is presented in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF CARNITINE IN INTERMEDIARY METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    is an important intermediary in fat metabolism. It is required to shuttle long-chain fatty acids, in the form of acylcarnitines, into mitochondria for beta-oxidation; carnitine is, therefore, crucial for energy production in tissues dependent upon fatty acid oxidation, such as cardiac and skeletal muscle.",
"   </p>",
"   <p>",
"    Reactions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    with activated fatty acids (acyl CoA) are esterifications of the general form",
"   </p>",
"   <p>",
"    acyl CoA &nbsp;+ &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    &nbsp; -&gt; &nbsp; acylcarnitine &nbsp;+ &nbsp;CoASH",
"   </p>",
"   <p>",
"    and are catalyzed by a family of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    acyltransferases.",
"   </p>",
"   <p>",
"    Besides fatty acid oxidation, functions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    include modulating the concentration of CoA, scavenging toxic acyl groups, and facilitating their transport out of mitochondria. Impaired fatty acid metabolism and consequent accumulation of acyl CoA are characteristic of renal failure. Acyl CoAs inhibit numerous enzymes important in intermediary metabolism and thereby increase insulin resistance, apoptosis, generation of free radicals and lipid peroxidation products. Conversion of acyl CoA to acylcarnitine and transport out of mitochondria constitutes a normal scavenger system for toxic acyl groups that are generated in excess in renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RENAL HANDLING AND METABOLISM OF CARNITINE IN RENAL FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    is derived from red meat and dairy products in the diet, biosynthesis in the liver, kidney, and brain is adequate to meet normal requirements in healthy individuals. About 95 percent of carnitine is stored in muscle, where it is concentrated by a specific transporter. Free carnitine is filtered at the glomerulus and over 90 percent undergoes tubular reabsorption. By contrast, renal tubular absorption of acylcarnitine is limited, and clearance of acylcarnitine is four to eight times greater than that of free carnitine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/3\">",
"     3",
"    </a>",
"    ]. Such differential clearance is consistent with the concept that esterification with carnitine is a pathway for detoxification and elimination of toxic acyl groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alterations in chronic kidney dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic kidney dysfunction, clearance of both free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    and acylcarnitine is reduced. Plasma levels of free and total carnitine are unchanged but serum acylcarnitine rises in inverse relation to decline of glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/5\">",
"     5",
"    </a>",
"    ]. The ratio of acylcarnitine to free carnitine is markedly increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metabolism in hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hemodialysis patients, plasma total",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    concentration is normal or elevated; the free carnitine concentration is reduced (19.2-32.4",
"    <span class=\"nowrap\">",
"     umol/L)",
"    </span>",
"    and significantly lower than in healthy controls (40-50",
"    <span class=\"nowrap\">",
"     umol/L)",
"    </span>",
"    or in chronic kidney disease (CKD); the acylcarnitine concentration is markedly increased and the ratio of acyl to free carnitine (AC:FC) is markedly increased (0.77-0.96) compared to healthy controls (0.15-0.25) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors contribute to this abnormal profile [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of renal parenchyma removes a source of endogenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      synthesis.",
"     </li>",
"     <li>",
"      Low dietary intake of meat and dairy products deprives patients of a rich source of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Hemodialysis removes free",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      and acylcarnitine. Although total dialytic removal is probably comparable to normal urinary excretion, free carnitine clearance by hemodialysis is greater than that of acylcarnitine. This pattern is the reverse of normal urinary carnitine excretion.",
"     </li>",
"     <li>",
"      Fatty acid metabolism is impaired in renal failure. Thus, incompletely metabolized acyl residues accumulate and drive the formation of acylcarnitine esters.",
"     </li>",
"     <li>",
"      The normal preferential renal excretion of acylcarnitine is lost in renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolism in peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in peritoneal dialysis patients has not been sufficiently studied. Available information indicates that total and free plasma carnitine are normal, and plasma acylcarnitine is elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Carnitine deficiency and dialysis patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;An AC:FC ratio greater than 0.4 indicates a disorder of fatty acid metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Excessive generation of acyl moieties because of incomplete fatty acid oxidation enhances formation of acylcarnitines and uses up free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    ; thus, a high AC:FC ratio and free carnitine deficiency may be a consequence as well as a cause of abnormal fatty acid metabolism. Conversion to intensive (nocturnal) hemodialysis (five to six sessions per week, eight hours per treatment) reduced free- and acylcarnitine levels and improved (reduced) the AC:FC ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/7\">",
"     7",
"    </a>",
"    ]. This improvement could be due to amelioration of impaired fatty acid oxidation.",
"   </p>",
"   <p>",
"    Effective",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency exists if free carnitine is inadequate to meet metabolic needs; such carnitine deficiency further impairs fatty acid oxidation. However, the plasma carnitine profile does not predict whether effective carnitine deficiency exists. The vast majority (95 percent) of hemodialysis patients have low free plasma carnitine, but neither plasma total, free, or acylcarnitine nor their ratios predict clinical response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. By comparison, tissue (muscle or erythrocyte) total carnitine levels sometimes correlate with clinically significant endpoints (see below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-Carnitine",
"    </a>",
"    supplementation increases plasma total, free, and acylcarnitine levels; the AC:FC ratio falls (improves) only moderately and incompletely, suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    continues to bind acyl residues that are present in excess in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decline of free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    levels depends on dialysis vintage. In a study of 21 patients, plasma",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    levels principally decreased within the first few months of beginning hemodialysis, while levels in muscle continued to decline even after one year of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/10\">",
"     10",
"    </a>",
"    ]. These findings are consistent with a pharmacokinetic model of L-carnitine in patients receiving hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF CARNITINE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of our knowledge of the consequences of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency comes from inherited cases in children. In these children without kidney disease, the features of carnitine deficiency include muscle weakness, acute encephalopathy, hepatic dysfunction, cardiomyopathy, nonketotic hypoglycemia, frequent infections, and failure to thrive.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    deficiency in dialysis patients has been termed Dialysis-related Carnitine Deficiency (DCD); it is distinguished from primary and secondary carnitine deficiency syndromes on the grounds that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      deficiency in DCD is relative and due to disparity between carnitine availability and metabolic needs.",
"     </li>",
"     <li>",
"      The ratio of acylcarnitine to free",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      is increased.",
"     </li>",
"     <li>",
"      Symptomatic improvement requires pharmacological doses rather than physiological replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CARNITINE SUPPLEMENTATION IN DIALYSIS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to clearly ascribe benefits with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation in dialysis patients because of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The symptoms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency (including muscle weakness and cardiomyopathy) overlap with those of dialysis patients generally.",
"     </li>",
"     <li>",
"      Laboratory evidence of abnormal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      metabolism is ubiquitous in this population.",
"     </li>",
"     <li>",
"      The response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      supplementation cannot be predicted from plasma carnitine profiles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are numerous studies supporting the view that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation improves the plasma lipid profile, exercise capacity and oxygen utilization, muscle strength, intradialytic symptoms, sense of well-being, hospitalization rate, inflammatory markers, protein metabolism, left ventricular hypertrophy and cardiac function, anemia, and response to erythropoietin. In many of these instances, the physiological rationale for administration of L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    is appealing.",
"   </p>",
"   <p>",
"    However, data evaluating these possible benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation in hemodialysis patients are limited, with many trials being uncontrolled and small in size. Although some controlled prospective studies have been performed, trials have been limited by small size, inclusion of patients independent of signs and symptoms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency, and relatively short follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, a growing literature supports benefits with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation on inflammation and muscle wasting. However, the evidence is unclear that L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation in dialysis patients improves exercise capacity, cardiomyopathy, or intradialytic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Protein and muscle catabolism and signs of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of acyl CoA to increase insulin resistance and generation of free radicals and lipid peroxidation products suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency may contribute to muscle wasting in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, results from different trials have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    has beneficial effects on inflammation, the oxidative state, and protein metabolism in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/4,9,12-14\">",
"     4,9,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      supplementation reduced BUN and plasma concentrations of creatinine and phosphate compared to placebo, and increased mid-arm muscle circumference, suggesting a decline in muscle catabolism; however, the constancy of delivered dialysis and diet was not verified [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two placebo-controlled trials in hemodialysis patients independently demonstrated that intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      body weight three times a week for six months) reduced serum C-reactive protein and increased albumin, transferrin and body mass index [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A randomized controlled trial showed that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      administration reduced serum amyloid A protein in dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation may therefore be considered in the patient with muscle wasting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation as defined by weight loss that is not otherwise explained, high C-reactive protein level,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreasing anthropometric measures (eg, mid-arm muscle circumference).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lipid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation increases fatty acid oxidation and reduces myocardial fatty acid retention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/4\">",
"     4",
"    </a>",
"    ], it is plausible that such supplementation may improve hyperlipidemia in this population. However, there is no consensus on the effect of L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    on hyperlipidemia (elevated triglycerides and reduced HDL cholesterol) in hemodialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .) A 2002 meta-analysis, for example, found no beneficial effect of L-carnitine on serum lipid profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These negative results may be due to the use of different dosages",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    route of administration. A low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    (less than 5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    significantly improved the lipid profile [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/17\">",
"     17",
"    </a>",
"    ] or modestly reduced elevated serum triglyceride levels [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/18\">",
"     18",
"    </a>",
"    ], while a dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously after each hemodialysis treatment had no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/8\">",
"     8",
"    </a>",
"    ]. High levels of carnitine may stimulate fatty acid (and hence triglyceride) synthesis rather than oxidation, which could explain this dose-dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Exercise limitation and oxygen consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation to improve exercise performance in patients receiving hemodialysis is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/9,19-22\">",
"     9,19-22",
"    </a>",
"    ]. Some studies demonstrated that L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation improved muscle strength but not endurance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, when muscle metabolism and function were assessed by magnetic resonance or near-infrared spectroscopy, L-carnitine supplementation for sixteen weeks in patients receiving maintenance hemodialysis showed no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These disparate results for the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation on exercise capacity may reflect a failure to select a severely",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    -deficient population, such as long-term dialysis patients. They also suggest that impairment of muscle energetics in some dialysis patients is due not only to carnitine deficiency but to other defects in fatty acid metabolism, such as carnitine palmitoyl transferase deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intradialytic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    may improve cardiac and skeletal muscle energy metabolism, thereby possibly ameliorating intradialytic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/9\">",
"     9",
"    </a>",
"    ]. However, a 2008 meta-analysis that included 193 patients found no effect of L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    on intradialytic hypotension, and only a tendency to ameliorate muscle cramps that did not achieve statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, a randomized study that was published after the meta-analysis and included 92 hemodialysis patients showed no effect of L-carnitine supplementation on hypotensive episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence examining whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation improves quality of life is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/9,19,25,26\">",
"     9,19,25,26",
"    </a>",
"    ]. Clinical status and sense of wellbeing, as reported by patients and staff, were significantly improved in one controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/9\">",
"     9",
"    </a>",
"    ] but not in two other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. In a randomized controlled trial of 50 patients studied for 24 weeks,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation improved SF-36 scores and reduced erythropoietin doses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in the randomized trial cited above, L-carnitine supplementation had no effect on the SF-36 scores and did not change erythropoietin responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/24\">",
"     24",
"    </a>",
"    ]. The effect of carnitine supplementation on erythropoietin responsiveness is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=see_link&amp;anchor=H4#H4\">",
"     \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation on rates of hospitalization is unclear. Review of CMS administrative data for prevalent hemodialysis patients in the years 1998 to 2003 revealed that infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     g/session",
"    </span>",
"    for at least 10 sessions in a month was associated with a statistically significant reduction of 10.8 percent in subsequent months' hospital days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/27\">",
"     27",
"    </a>",
"    ]. However, a causal relationship cannot be inferred. It is important to note that no existing randomized trials have addressed this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anemia and response to erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    may be effective in patients with chronic renal disease and anemia. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=see_link&amp;anchor=H3#H3\">",
"     \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\", section on 'L-carnitine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observations of benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation in trials with small numbers of patients include partial reversal of cardiomegaly, improvement of left ventricular ejection fraction, and reductions in cardiac arrhythmias and anginal episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. A multicenter, randomized controlled trial showed that L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in large doses ameliorated left ventricular dilatation after myocardial infarction, but this study was not done in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CONSENSUS STATEMENTS AND GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several consensus conferences as well as the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    working groups that developed guidelines for nutrition and for anemia in chronic renal failure concluded that routine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation in dialysis patients was NOT justified by available information [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Several of these groups suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation may be considered in the following settings when standard therapy had not been effective [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intradialytic hypotension or muscle cramps",
"     </li>",
"     <li>",
"      Muscle weakness and lack of functional wellbeing",
"     </li>",
"     <li>",
"      Decreased exercise capacity or low peak oxygen consumption",
"     </li>",
"     <li>",
"      Cardiomyopathy and low cardiac output",
"     </li>",
"     <li>",
"      Anemia of renal failure that is unresponsive to or requires large doses of erythropoietin&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=see_link&amp;anchor=H3#H3\">",
"       \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\", section on 'L-carnitine'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 1999, the Food and Drug Administration approved the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    in dialysis-related",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/36\">",
"     36",
"    </a>",
"    ]. In 2003, the Center for Medicare and Medicaid Services (CMS) approved reimbursement for use of L-carnitine in treatment of hemodialysis patients only with erythropoietin-resistant anemia or intradialytic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/37\">",
"     37",
"    </a>",
"    ]. The wisdom of providing reimbursement for an unproven agent has been challenged [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/38\">",
"     38",
"    </a>",
"    ], while others have questioned why use of L-carnitine in dialysis patients is not more widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few, if any, adverse effects of intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    . Thus, the major deterrent to an empiric trial in patients with symptoms compatible with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency is cost and convenience.",
"   </p>",
"   <p>",
"    The evidence is not definitive that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation in dialysis patients improves exercise capacity, cardiomyopathy, or intradialytic symptoms. On the other hand, a growing body of work supports benefit on inflammation and muscle wasting. Since many of the putative benefits of L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    remain anecdotal and are confined to an unpredictable subset of the dialysis population, refinement of the definition of carnitine deficiency in dialysis patients is needed to better understand the use of the agent in this setting.",
"   </p>",
"   <p>",
"    As response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation cannot be predicted from laboratory evidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency, close follow-up and objective clinical end points are required when L-carnitine supplements are prescribed. Physicians should be hesitant to add the cost of this supplement to the high expense of maintenance dialysis if an empiric course of treatment shows no benefit.",
"   </p>",
"   <p>",
"    The National Kidney Foundation (NKF)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    Consensus Conference recommended that the clinical response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    be evaluated at three-month intervals and the agent discontinued if no clinical improvement has occurred within nine to twelve months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/35\">",
"     35",
"    </a>",
"    ]. Measurement of plasma carnitine levels to predict response or monitor treatment has not been useful. However, CMS has required a predialysis plasma-free carnitine level below 40",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    to qualify L-carnitine administration for reimbursement.",
"   </p>",
"   <p>",
"    Despite the recommendations of expert consensus groups and the approval of reimbursement by the Centers for Medicare and Medicaid Services (CMS), we do not believe that existing evidence is strong enough to endorse the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    for any of the indications for which it has been recommended. Potential uses of L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in dialysis patients include anemia resistant to erythopoesis-stimulating agents, dialysis-related hypotension, muscle wasting, weight loss, biochemical evidence of inflammation, and cardiomyopathy. The expense of intravenous administration of L-carnitine is an important reason to discourage its use, especially if medical resources become increasingly scarce. As an intravenous medication, L-carnitine is included in the bundle of reimbursed dialysis services and therefore not specifically reimbursed. National dialysis chains do not approve L-carnitine for use in their patients, a decision with which we agree. If L-carnitine is administered, the course should be limited to three to six months and objective evidence of benefit should be sought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     L-carnitine dose and route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the toxicity of D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , racemic mixtures of D- and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used. Optimal dosing is not defined for L-carnitine. The Food and Drug Administration (FDA) approved use specifically of the intravenous formulation of L-carnitine in dialysis patients. A dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously after dialysis has been employed in several controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/8,9,12-14\">",
"     8,9,12-14",
"    </a>",
"    ], and has been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. Higher doses (up to 100",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    have been used, but total doses above 3 grams may increase platelet aggregation. Lower doses (less than 5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    have been used in hyperlipidemias [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    is NOT recommended because of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High oral doses are required because of limited bioavailability [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/39\">",
"       39",
"      </a>",
"      ]. In addition, data on the efficacy of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      are limited.",
"     </li>",
"     <li>",
"      Toxic metabolites of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      are generated due to intestinal metabolism; this first results in trimethylamine (TMA), which is further metabolized in the liver to trimethylamine-n-oxide (TMNO). These toxic metabolites accumulate between dialysis sessions even in patients who are not receiving oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      supplements but are efficiently cleared by dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/40\">",
"       40",
"      </a>",
"      ]. In dialysis patients who receive oral L-carnitine 1 g daily, plasma concentrations of TMNO continue to rise after two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/41\">",
"       41",
"      </a>",
"      ]. TMA and TMNO may cause cognitive impairment and malodorous breath characteristic of uremia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14200/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In hemodialysis patients, plasma total",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      concentration is normal or elevated, and the free carnitine concentration is reduced. Although effective carnitine deficiency exists if free carnitine is inadequate to meet metabolic needs, the plasma carnitine profile does NOT predict whether effective carnitine deficiency exists. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Renal handling and metabolism of carnitine in renal failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency but without kidney disease, the features of carnitine deficiency include muscle weakness, acute encephalopathy, hepatic dysfunction, cardiomyopathy, nonketotic hypoglycemia, frequent infections, and failure to thrive. Carnitine deficiency in dialysis patients (DCD) is distinguished from these carnitine deficiency syndromes in that DCD is relative and due to the disparity between carnitine availability and metabolic needs, and symptomatic improvement requires pharmacological doses rather than physiological replacement. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features of carnitine deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is often difficult to ascribe benefits to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      supplementation in dialysis patients. This is because the symptoms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency overlap with those of dialysis patients generally, laboratory evidence of abnormal carnitine metabolism is ubiquitous, and the response to carnitine supplementation cannot be predicted from plasma carnitine profiles. It is, however, safe for long-term administration, at least by the intravenous route. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Carnitine supplementation in dialysis patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no strong evidence that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      supplementation in dialysis patients improves muscle wasting or weight loss, exercise capacity, cardiomyopathy, or intradialytic symptoms, although it appears to be safe. Among dialysis patients, we recommend NOT administering oral L-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Carnitine supplementation in dialysis patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hoppel, C. The physiological role of carnitine. In: L-Carnitine and Its Role in Medicine: From Function to Therapy, Ferrari, R, DiMauro, S, Sherwood, G (Eds), Academic Press, London, 1992, pp. 5-19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/2\">",
"      Wanner C, H&ouml;rl WH. Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects. Nephron 1988; 50:89.",
"     </a>",
"    </li>",
"    <li>",
"     Ahmad, S. Carnitine, kidney and renal dialysis. In: L-Carnitine and Its Role in Medicine: From Function to Therapy, Ferrari, R, DiMauro, S, Sherwood, G (Eds), Academic Press, London, 1992, p. 381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/4\">",
"      Schreiber BD. Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients. Blood Purif 2006; 24:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/5\">",
"      Fouque D, Holt S, Guebre-Egziabher F, et al. Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease. J Ren Nutr 2006; 16:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/6\">",
"      Golper, TA, Ahmad, S. L-carnitine administration to hemodialysis patients: has its time come?. Semin Dial 1992; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/7\">",
"      Hothi DK, Geary DF, Fisher L, Chan CT. Short-term effects of nocturnal haemodialysis on carnitine metabolism. Nephrol Dial Transplant 2006; 21:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/8\">",
"      Golper TA, Wolfson M, Ahmad S, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 1990; 38:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/9\">",
"      Ahmad S, Robertson HT, Golper TA, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990; 38:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/10\">",
"      Evans AM, Faull RJ, Nation RL, et al. Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int 2004; 66:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/11\">",
"      Fornasini G, Upton RN, Evans AM. A pharmacokinetic model for L-carnitine in patients receiving haemodialysis. Br J Clin Pharmacol 2007; 64:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/12\">",
"      Savica V, Santoro D, Mazzaglia G, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 2005; 15:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/13\">",
"      Duranay M, Akay H, Yilmaz FM, et al. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 2006; 21:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/14\">",
"      Biolo G, Stulle M, Bianco F, et al. Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 2008; 23:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/15\">",
"      Tabibi H, Hakeshzadeh F, Hedayati M, Malakoutian T. Effects of l-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: a randomized controlled trial. J Ren Nutr 2011; 21:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/16\">",
"      Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/17\">",
"      Wanner C, Wieland H, W&auml;ckerle B, et al. Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients. Kidney Int Suppl 1989; 27:S264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/18\">",
"      Elisaf M, Bairaktari E, Katopodis K, et al. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol 1998; 18:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/19\">",
"      Fagher B, Cederblad G, Eriksson M, et al. L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Lab Invest 1985; 45:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/20\">",
"      Siami G, Clinton ME, Mrak R, et al. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 1991; 57:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/21\">",
"      Thompson CH, Irish AB, Kemp GJ, et al. The effect of propionyl L-carnitine on skeletal muscle metabolism in renal failure. Clin Nephrol 1997; 47:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/22\">",
"      Vaux EC, Taylor DJ, Altmann P, et al. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 2004; 97:c41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/23\">",
"      Lynch KE, Feldman HI, Berlin JA, et al. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis. Am J Kidney Dis 2008; 52:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/24\">",
"      Mercadal L, Coudert M, Vassault A, et al. L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol 2012; 7:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/25\">",
"      Semeniuk J, Shalansky KF, Taylor N, et al. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients. Clin Nephrol 2000; 54:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/26\">",
"      Steiber AL, Davis AT, Spry L, et al. Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. JPEN J Parenter Enteral Nutr 2006; 30:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/27\">",
"      Weinhandl ED, Rao M, Gilbertson DT, et al. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003. Am J Kidney Dis 2007; 50:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/28\">",
"      Romagnoli GF, Naso A, Carraro G, Lidestri V. Beneficial effects of L-carnitine in dialysis patients with impaired left ventricular function: an observational study. Curr Med Res Opin 2002; 18:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/29\">",
"      Signorelli SS, Fatuzzo P, Rapisarda F, et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. Drugs Aging 2006; 23:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/30\">",
"      Signorelli SS, Fatuzzo P, Rapisarda F, et al. Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res 2006; 29:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/31\">",
"      Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995; 26:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/32\">",
"      Consensus Group Statement. Role of L-carnitine in treating renal dialysis patients. Dial Transplant 1994; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/33\">",
"      Dialysis Outcomes Quality Initiative Guidelines. Clinical practice guidelines for nutrition in chronic renal failure, Guideline 22. Am J Kidney Dis 2000; 35(Suppl 2):S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/34\">",
"      NKF-K/DOQI Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(Suppl 3):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/35\">",
"      Eknoyan G, Latos DL, Lindberg J, National Kidney Foundation Carnitine Consensus Conference. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 2003; 41:868.",
"     </a>",
"    </li>",
"    <li>",
"     FDA summary of approval for carnitor injection in dialysis. NDA:20-182/s-006, Dec 1999",
"    </li>",
"    <li>",
"     Medicare Coverage Policy: Levocarnitine for end-stage renal disease decision memorandum. 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/38\">",
"      Steinman TI. L-carnitine supplementation in dialysis patients: does the evidence justify its use? Semin Dial 2005; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/39\">",
"      Brass EP. Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 1995; 17:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/40\">",
"      Bain MA, Faull R, Fornasini G, et al. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 2006; 21:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/41\">",
"      Bain MA, Faull R, Milne RW, Evans AM. Oral L-carnitine: metabolite formation and hemodialysis. Curr Drug Metab 2006; 7:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14200/abstract/42\">",
"      Schreiber B. Safety of oral carnitine in dialysis patients. Semin Dial 2002; 15:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1967 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14200=[""].join("\n");
var outline_f13_55_14200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF CARNITINE IN INTERMEDIARY METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RENAL HANDLING AND METABOLISM OF CARNITINE IN RENAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alterations in chronic kidney dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metabolism in hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolism in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Carnitine deficiency and dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES OF CARNITINE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CARNITINE SUPPLEMENTATION IN DIALYSIS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Protein and muscle catabolism and signs of inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lipid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Exercise limitation and oxygen consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intradialytic complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anemia and response to erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CONSENSUS STATEMENTS AND GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      L-carnitine dose and route of administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=related_link\">",
"      Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_55_14201="Human herpesvirus 7 infection";
var content_f13_55_14201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human herpesvirus 7 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14201/contributors\">",
"     Cecile Tremblay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14201/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14201/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/55/14201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 7 (HHV-7) was first isolated in 1990 from the CD4+ T cells of a healthy individual whose activated cells in culture showed cytopathic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/1\">",
"     1",
"    </a>",
"    ]. Although its structure has been well characterized, its role in human disease has yet to be defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-7 belongs to the Roseolovirus genus of the herpesvirus subfamily. Its linear double-stranded DNA genome of about 145 kb shows homologies to human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV). Mature HHV-7 particles measure 170 nm in diameter, with nucleocapsids of 90 to 95 nm and a tegument of approximately 30 nm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/2\">",
"     2",
"    </a>",
"    ]. Its DNA codes for 84 different proteins including two major capsid proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HHV-7 genome is co-linear with the HHV-6 genome and approximately 10 percent shorter. The overall arrangement of the genomes is similar for the two viruses. The primary divergences from HHV-6 are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of the adeno-associated virus type 2 (AAV-2) rep gene homologue found in HHV-6 (open reading frame [ORF] U94), which is associated with the viral origin of DNA replication [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Divergent binding properties between the respective origin binding proteins (OBPs) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lack of two spliced exons (ORFs U96, U97) that encode portions of the major HHV-6 virion glycoprotein gp 105.",
"     </li>",
"     <li>",
"      The inclusion of genes encoding putative viral transactivator proteins and the DR element, which specify ORFs of different coding capacities than HHV-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The significance of these differences for viral DNA replication is unknown.",
"   </p>",
"   <p>",
"    In common with HHV-6, HHV-7 contains two ORFs (U12, U51) that encode putative G-protein-coupled receptors. Further analysis demonstrates that they encode functional calcium-mobilizing receptors for beta-chemokines, which include thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC), EBI1-ligand chemokine (ELC), and secondary lymphoid-tissue chemokine (SLC) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These ORFs encode a transmembrane glycoprotein (gB), which is thought to represent one of the HHV-7 envelope proteins involved in the adsorption of virus-to-cell surface proteoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/7\">",
"     7",
"    </a>",
"    ]. These ORFs also encode two other glycoproteins (gH) and (gL) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/8\">",
"     8",
"    </a>",
"    ], a",
"    <span class=\"nowrap\">",
"     phosphotransferase/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"      ganciclovir",
"     </a>",
"    </span>",
"    kinase, a ribonucleotide reductase, a protease, and a heparin-binding gp 65 that may contribute to viral attachment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Some genetic diversity in gB and gH has been observed, suggesting possible use in the classification of HHV-7 isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. HHV-7 ORF U47 encodes gO-gH complex which may have similar function to that in HCMV and HHV-6, such as cell to cell fusion in viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-7 ORF U12 activates distinct transmembrane signaling pathways that may mediate biologic functions by binding with a beta-chemokine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, an HHV-7 glycoprotein U21 is an immunoevasin that binds to class I major histocompatibility complex molecules and diverts them to a lysosomal compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. U24, a protein common to roseola viruses that is known to downregulate the T cell receptor has also been shown to downregulate a transferrin receptor, blocking early endosomal recycling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human antibodies raised in response to HHV-7 are directed against the immunodominant protein pp85 encoded by ORF (U14) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cell tropism",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-7 is a lymphotropic virus which replicates in CD4+ T lymphocytes. It can be induced from latency within T-cells by cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/21\">",
"     21",
"    </a>",
"    ]. It can also be cultured in a CD4+ lymphoblastic cell line (SupT1) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/2,22\">",
"     2,22",
"    </a>",
"    ], in cord blood mononuclear cells (CBMC), and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/23\">",
"     23",
"    </a>",
"    ]. Its in vitro host-cell range is narrower than HHV-6. It does not infect certain CD4+ cell lines such as Jurkat and H-9 HeLa-CD4 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/24\">",
"     24",
"    </a>",
"    ] but may be able to infect CD4-positive hematopoietic precursor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. HHV-7 has been detected in CD68+",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    associated with Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Viral entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-7, unlike HHV-6, utilizes CD4 as a cellular receptor for entry into CD4+ cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. CD4 expression is necessary, but not sufficient, for infection of T cells as evidenced by its inability to penetrate many cell lines expressing CD4+ such as HeLa- CD4 or Jurkat.",
"   </p>",
"   <p>",
"    Among other co-factors that might allow HHV-7 entry are cell-surface proteoglycans, which are capable of binding to HHV-7 glycoprotein B (gB) and are present on SupT1 cells but not on other CD4+ T cell lines resistant to HHV-7 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/7\">",
"     7",
"    </a>",
"    ]. HHV-7 induces a profound downregulation of CD4 expression, which occurs six to nine days after infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] through a suppressive effect on CD4 transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, HHV-7 infection interferes with HIV-1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/28,33\">",
"     28,33",
"    </a>",
"    ]. HHV-7 does not require CXCR4 for entry [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/34\">",
"     34",
"    </a>",
"    ] but may downregulate its expression with potential implication for HIV-1 coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .) It may reactivate HHV-6 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/21,36\">",
"     21,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effects on cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-7 has a variety of effects on cells:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-7 is more cell-associated, less cytopathic, and grows with slower kinetics in culture than HHV-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar to HIV-1 and HHV-6, the cytopathic effect (CPE) of HHV-7 is characterized by membrane blebbing and the presence of multinucleated giant cells (syncytia) that eventually undergo necrotic lysis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/1,38\">",
"       1,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-7 can induce apoptosis in a number of cell types [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/32,39,40\">",
"       32,39,40",
"      </a>",
"      ], an effect that may be mediated via the TRAIL pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-7 can also support latent infection as evidenced by the absence of viral transcripts the peripheral blood mononuclear cells of healthy donors infected with HHV-7 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunomodulatory effects on cytokines have been described in vitro, such as increases in tumor necrosis factor (TNF)-alpha, interferon (INF)-gamma, transforming growth factor (TGF)-beta, and interleukin (IL)-15, and a decrease in IL-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. No effect has been observed on IL-4 and IL-6. Recent ex vivo and in vivo experiments have demonstrated that HHV-7 down-modulates expression of HLA and B2-microglobulin. This could help viral escape from host immune pressure and partly explain HHV-7 persistence in infected cells [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-7 is ubiquitous. More than 95 percent of adults are seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/46\">",
"     46",
"    </a>",
"    ]. Infection with HHV-7 generally occurs during childhood but peaks at a later age than infection with HHV-6, usually around three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    .) HHV-7 appears to be shed throughout life in saliva, and 75 percent of healthy adults secrete HHV-7 at some time in saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/33,48-51\">",
"     33,48-51",
"    </a>",
"    ]. Intrafamilial transmission has been documented using restriction analyses of HHV-7 genome from virus recovered from saliva of individuals within a family [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/50\">",
"     50",
"    </a>",
"    ]. The average number of genome copies is higher than that of HHV-6, and this amount is stable over time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-7 DNA has been detected in breast milk in 3 of 29 samples studied, suggesting that breastfeeding could be one route of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/53\">",
"     53",
"    </a>",
"    ]. It has also been isolated from cervical secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/54\">",
"     54",
"    </a>",
"    ]. HHV-7 DNA can be detected in the PBMCs of most healthy adults at a level of approximately 300 copies per million cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/55\">",
"     55",
"    </a>",
"    ], but infectious virus cannot be isolated from unstimulated PBMC cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. HHV-7 DNA has also been detected in 50 percent of bone marrow samples from 18 healthy patients who had undergone hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/56\">",
"     56",
"    </a>",
"    ], and in bronchoalveolar lavage fluid of 32 percent and 21 percent of hospitalized adult transplant and nontransplant patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study seeking to identify risk factors for HHV-7 infection, seasonal factors and black race were associated with a higher prevalence of HHV-7 infection among children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/58\">",
"     58",
"    </a>",
"    ]. A history of ever having been breastfed seemed to have a protective effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-7 infection is generally asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies suggest that HHV-7 shares similar clinical features with HHV-6. In one prospective study, 15 of 71 infants and children (21 percent) who presented for acute febrile respiratory illness with or without skin rash were infected with HHV-7. Fever was observed in all 15, which persisted for 2.9 days. A papular, macular or maculopapular rash was observed in 14, appearing on the face, trunk and extremities as fever subsided and lasting for 2.7 days. A simultaneous increase in antibody titers to HHV-6 was observed in 8 of the 15 (53 percent) during primary HHV-7 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/59\">",
"     59",
"    </a>",
"    ]. In another study, 8 of 250 (3 percent) children with acute febrile illness or seizure were HHV-7 infected compared to 29 out of 250 (12 percent) who were infected with HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/60\">",
"     60",
"    </a>",
"    ]. Low lymphocyte counts, rash, vomiting, diarrhea were present.",
"   </p>",
"   <p>",
"    HHV-7 has been identified as one of the viruses causing exanthem subitum (ES, roseola) although HHV-6 is more common. One study demonstrated seroconversion to HHV-7 in five of seven infants immediately after exhibiting typical signs and symptoms of ES [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28982?source=see_link\">",
"     \"Roseola infantum (exanthem subitum)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated cases of encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/62\">",
"     62",
"    </a>",
"    ], hemiconvulsion and hemiplegia syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/63\">",
"     63",
"    </a>",
"    ], and hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/64\">",
"     64",
"    </a>",
"    ] have been reported during HHV-7 infection, while a mononucleosis-like syndrome has been associated with reactivation of Epstein Barr virus by HHV-7 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children &le;24 months of age, HHV-7 infections occur less often than HHV-6 infections. In one study, of 2806 samples from 2365 children &le;10 years old, 30 (1 percent) showed evidence of HHV-7 viremia; 23 (77 percent) of these were primary and 7 (23 percent) were reactivated HHV-7 infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/67\">",
"     67",
"    </a>",
"    ]. Four (13 percent) showed concurrent HHV-6 viremia, two associated with primary HHV-7 infections. The clinical manifestations of primary and reactivated HHV-7 infections were similar, except that seizures occurred more frequently in reactivated infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Febrile seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infection with HHV-7 and HHV-6 has been associated with febrile seizures. An association with HHV-7 and febrile convulsions has been described in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. As noted above, HHV-7 isolation has been described from infants with ES, including a report of two cases of seizures and acute hemiplegia complicating this entity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Whether this syndrome can be attributed to HHV-7 infection itself or to its ability to reactivate HHV-6 var B from latency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/21\">",
"     21",
"    </a>",
"    ] remains unknown, although some findings such as rising anti-HHV-6 antibody titers in sera from convalescent infants or excretion of HHV-6 DNA in saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/75,76\">",
"     75,76",
"    </a>",
"    ] would suggest that coinfection plays a role in pathogenesis. One case of acute myeloradiculoneuropathy associated with HHV-7 has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pityriasis rosea",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association of HHV-7 with pityriasis rosea (PR) has been suggested by the presence of HHV-7 DNA in cell-free plasma, seroconversion to the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/78-80\">",
"     78-80",
"    </a>",
"    ], and viral particles suggestive of HHV-7 on electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/81\">",
"     81",
"    </a>",
"    ]. In contrast to these observations, one study failed to detect HHV-7 DNA sequences or antigens in skin lesions from PR patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/82\">",
"     82",
"    </a>",
"    ]. Lichen planus (LP), a common inflammatory skin disease has also been associated with HHV-7, as demonstrated by HHV-7 DNA through PCR testing in LP lesions as compared to patients with psoriasis and healthy controls. A causal association, however, remains to be demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     HHV-7 and AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although in vitro studies have shown interference between HIV-1 and HHV-7, the clinical implications of these interactions are not fully understood [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/84\">",
"     84",
"    </a>",
"    ]. In one study, HHV-7 DNA was detected less frequently in a group of patients with the acquired immunodeficiency syndrome (AIDS) than among 15 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/85\">",
"     85",
"    </a>",
"    ]. However, in another study, detection and viral load of HHV-7 in saliva were found to be increased in HIV-1 infected subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-7 has also been demonstrated by immunohistochemistry in five out of seven lymph nodes of HIV-infected subjects compared to one out of five of HIV-negative subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/87\">",
"     87",
"    </a>",
"    ]. In a study comparing healthy blood donors with HIV-1 infected subjects with various degrees of disease progression, HHV-7 infection did not appear to be stimulated by HIV-1 infection, nor interact with it. Rather, HHV-7 correlated with CD4+ T-lymphocyte counts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-7 may be a cofactor for symptomatic CMV infection in renal transplant recipients. In several studies of such patients, those with symptomatic CMV disease were more likely to have prior and concurrent HHV-7 DNA in their peripheral blood lymphocytes than were patients with asymptomatic CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. In one study, renal transplant recipients with chronic allograft nephropathy had an increased incidence of HHV-6 and HHV-7 viremia compared with those without chronic allograft nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting reports about HHV-7 in bone marrow transplant recipients. In some studies, HHV-7 DNA in peripheral blood lymphocytes was associated with a longer time to neutrophil engraftment and with symptomatic CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/92,93\">",
"     92,93",
"    </a>",
"    ], whereas another study found only low levels of HHV-7 DNA in a minority of bone marrow transplant recipients, which did not change over a six month period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of HHV-7 infection in pediatric transplant patients have had conflicting results. In a prospective study of 59 pediatric patients followed 12 weeks after hematopoietic cell transplant (HCT), PCR revealed HHV-7 in blood samples in 56 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/95\">",
"     95",
"    </a>",
"    ]. The rate was higher in autologous compared to allogeneic grafts and there was no association with CMV, administration of colony stimulating factor, or acute graft-versus-host disease. In another study, prolonged reactivations appear to correlate with clinical symptoms such as fever, rash and bone marrow suppression, but severe complications were rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/96\">",
"     96",
"    </a>",
"    ]. However, another study found HHV-7 to be uncommon post-HCT (9 of 265), although it was associated with severe GVHD and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/97\">",
"     97",
"    </a>",
"    ]. The discrepancies between these results may be due to the sensitivity of the assay used and the design of the studies.",
"   </p>",
"   <p>",
"    Isolated cases of acute myelitis, optic neuritis, meningitis, and encephalitis have been described after stem cell transplantation in association with HHV-7 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/95,98-100\">",
"     95,98-100",
"    </a>",
"    ]. In addition, HHV-7 may be a cofactor in HHV-6 reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the above observations, no disease has been associated with HHV-7 following heart transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/102\">",
"     102",
"    </a>",
"    ] or intestinal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/103\">",
"     103",
"    </a>",
"    ], and the role of HHV-7 in morbidity after hepatic transplantation is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. In a study of 22 adult liver transplant recipients, 41 percent had HHV-7 viremia during a 90-day follow-up associated with either HHV-7 positive IgM or significant increases in IgG titers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/106\">",
"     106",
"    </a>",
"    ]. One small study in liver transplant recipients demonstrated that HHV-7 antigenemia usually occurred simultaneously with CMV antigenemia in patients with symptomatic CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/107\">",
"     107",
"    </a>",
"    ], whereas another showed that HHV-7 infection occurred independently of CMV in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/108\">",
"     108",
"    </a>",
"    ]. The clinical implications of these findings are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other possible disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies looking at a possible association of HHV-7 with Hodgkin lymphoma or non-Hodgkin lymphoma, T- and B-cell lymphoma have all been negative [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. The suggested association of HHV-6 to multiple sclerosis has prompted studies to evaluate the role of HHV-7 in this syndrome, but no association has been found [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/112-115\">",
"     112-115",
"    </a>",
"    ]. A case of veno-occlusive disease in a patient with X-linked agammaglobulinemia and HHV-7 infection of the explanted liver after transplantation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case-control study of infants with cerebral palsy in Australia has shown a 1.5 to 2.5 increased risk of developing cerebral palsy after perinatal exposure to herpes virus group B, as measured by PCR on dried blood spots. However, this does not prove any causal association [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of HHV-7 in connective tissue diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/118\">",
"     118",
"    </a>",
"    ], periodontitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/119\">",
"     119",
"    </a>",
"    ], as well as Graves&rsquo; disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/120\">",
"     120",
"    </a>",
"    ] is also being evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few clinical situations currently warrant the use of HHV-7 diagnostic assays, which are currently used mainly for research purposes. Several serologic tests, including early versions of indirect immunofluorescence (IFA) and enzyme linked immunosorbent assay (ELISA), have shown cross-reactivity with HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Newer assays based upon an 89 kDa HHV-7 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/123\">",
"     123",
"    </a>",
"    ] or glycoprotein B [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/124\">",
"     124",
"    </a>",
"    ] do not seem to cross-react with antibodies to HHV-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) assays have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/125-127\">",
"     125-127",
"    </a>",
"    ], while real-time PCR assays may quantify and differentiate herpesviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/128-130\">",
"     128-130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical settings in which treatment for HHV-7 infection is warranted have been identified. In vitro,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , CADA, and PMPA inhibit HHV-7 replication by achievable concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/131-133\">",
"     131-133",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    IC50 was &gt;7",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    IC50s were 121 and 18",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    Small clinical studies suggest that HHV-7 is resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    at levels that were effective for prevention and treatment of CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. Sensitivity of HHV-7 to the guanine analogs was different from HHV-6, suggesting a difference in selectivity of specific viral enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14201/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11242920\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of human herpesvirus 7 (HHV-7) in human disease has yet to be defined. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-7, which belongs to the herpesvirus subfamily, is a lymphotropic virus which replicates in CD4+ T lymphocytes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 95 percent of adults are HHV-7 seropositive. Infection with HHV-7 generally occurs during childhood, peaking around three years of age. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-7 infection is generally asymptomatic. Among children, HHV-7 has been associated with fever and rash and with febrile seizures. Among renal transplant recipients, HHV-7 may be a co-factor for symptomatic CMV disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At present, diagnostic assays for HHV-7 are only used in research settings. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clear indications for initiating treatment of HHV-7 infection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/1\">",
"      Frenkel N, Schirmer EC, Wyatt LS, et al. Isolation of a new herpesvirus from human CD4+ T cells. Proc Natl Acad Sci U S A 1990; 87:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/2\">",
"      Klussmann JP, Krueger E, Sloots T, et al. Ultrastructural study of human herpesvirus-7 replication in tissue culture. Virchows Arch 1997; 430:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/3\">",
"      Nicholas J. Determination and analysis of the complete nucleotide sequence of human herpesvirus. J Virol 1996; 70:5975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/4\">",
"      Megaw AG, Rapaport D, Avidor B, et al. The DNA sequence of the RK strain of human herpesvirus 7. Virology 1998; 244:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/5\">",
"      Krug LT, Inoue N, Pellett PE. Sequence requirements for interaction of human herpesvirus 7 origin binding protein with the origin of lytic replication. J Virol 2001; 75:3925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/6\">",
"      Tadagaki K, Nakano K, Yamanishi K. Human herpesvirus 7 open reading frames U12 and U51 encode functional beta-chemokine receptors. J Virol 2005; 79:7068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/7\">",
"      Secchiero P, Sun D, De Vico AL, et al. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol 1997; 71:4571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/8\">",
"      Mukai T, Hata A, Isegawa Y, Yamanishi K. Characterization of glycoprotein H and L of human herpesvirus 7. Microbiol Immunol 1997; 41:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/9\">",
"      Skrincosky D, Hocknell P, Whetter L, et al. Identification and analysis of a novel heparin-binding glycoprotein encoded by human herpesvirus 7. J Virol 2000; 74:4530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/10\">",
"      Skrincosky D, Willis RA, Hocknell PK, et al. Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies. Arch Virol 2001; 146:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/11\">",
"      Chan PK, Li CK, Chik KW, et al. Genetic variation of glycoproteins B and H of human herpesvirus 7 in Hong Kong. J Med Virol 2003; 71:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/12\">",
"      Thawaranantha D, Chimabutra K, Balachandra K, et al. Genetic variations of human herpesvirus 7 by analysis of glycoproteins B and H, and R2-repeat regions. J Med Virol 2002; 66:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/13\">",
"      Sadaoka T, Yamanishi K, Mori Y. Human herpesvirus 7 U47 gene products are glycoproteins expressed in virions and associate with glycoprotein H. J Gen Virol 2006; 87:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/14\">",
"      Nakano K, Tadagaki K, Isegawa Y, et al. Human herpesvirus 7 open reading frame U12 encodes a functional beta-chemokine receptor. J Virol 2003; 77:8108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/15\">",
"      Hudson AW, Blom D, Howley PM, Ploegh HL. The ER-lumenal domain of the HHV-7 immunoevasin U21 directs class I MHC molecules to lysosomes. Traffic 2003; 4:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/16\">",
"      Hudson AW, Howley PM, Ploegh HL. A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibility complex class I molecules to lysosomes. J Virol 2001; 75:12347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/17\">",
"      May NA, Glosson NL, Hudson AW. Human herpesvirus 7 u21 downregulates classical and nonclassical class I major histocompatibility complex molecules from the cell surface. J Virol 2010; 84:3738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/18\">",
"      Glosson NL, Gonyo P, May NA, et al. Insight into the mechanism of human herpesvirus 7 U21-mediated diversion of class I MHC molecules to lysosomes. J Biol Chem 2010; 285:37016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/19\">",
"      Sullivan BM, Coscoy L. The U24 protein from human herpesvirus 6 and 7 affects endocytic recycling. J Virol 2010; 84:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/20\">",
"      Stefan A, Secchiero P, Baechi T, et al. The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles. J Virol 1997; 71:5758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/21\">",
"      Katsafanas GC, Schirmer EC, Wyatt LS, Frenkel N. In vitro activation of human herpesviruses 6 and 7 from latency. Proc Natl Acad Sci U S A 1996; 93:9788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/22\">",
"      Cermelli C, Pietrosemoli P, Meacci M, et al. SupT-1: a cell system suitable for an efficient propagation of both HHV-7 and HHV-6 variants A and B. New Microbiol 1997; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/23\">",
"      Zhang Y, de Bolle L, Aquaro S, et al. Productive infection of primary macrophages with human herpesvirus 7. J Virol 2001; 75:10511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/24\">",
"      Berneman ZN, Ablashi DV, Li G, et al. Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. Proc Natl Acad Sci U S A 1992; 89:10552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/25\">",
"      Yasukawa M, Inoue Y, Ohminami H, et al. Human herpesvirus 7 infection of lymphoid and myeloid cell lines transduced with an adenovirus vector containing the CD4 gene. J Virol 1997; 71:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/26\">",
"      Mirandola P, Secchiero P, Pierpaoli S, et al. Infection of CD34(+) hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood 2000; 96:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/27\">",
"      Kempf W, Adams V, Wey N, et al. CD68+ cells of monocyte/macrophage lineage in the environment of AIDS-associated and classic-sporadic Kaposi sarcoma are singly or doubly infected with human herpesviruses 7 and 6B. Proc Natl Acad Sci U S A 1997; 94:7600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/28\">",
"      Lusso P, Secchiero P, Crowley RW, et al. CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus. Proc Natl Acad Sci U S A 1994; 91:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/29\">",
"      Miyake F, Yoshikawa T, Sun H, et al. Latent infection of human herpesvirus 7 in CD4(+) T lymphocytes. J Med Virol 2006; 78:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/30\">",
"      Furukawa M, Yasukawa M, Yakushijin Y, Fujita S. Distinct effects of human herpesvirus 6 and human herpesvirus 7 on surface molecule expression and function of CD4+ T cells. J Immunol 1994; 152:5768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/31\">",
"      Secchiero P, Gibellini D, Flamand L, et al. Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels. J Immunol 1997; 159:3412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/32\">",
"      Secchiero P, Flamand L, Gibellini D, et al. Human Herpesvirus 7 induces CD4(+) T-cell death by two distinct mechanisms: necrotic lysis in productively infected cells and apoptosis in uninfected or nonproductively infected cells. Blood 1997; 90:4502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/33\">",
"      Hall CB. Human herpesviruses at sixes, sevens, and more. Ann Intern Med 1997; 127:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/34\">",
"      Zhang Y, Hatse S, De Clercq E, Schols D. CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entry into CD4(+) T cells. J Virol 2000; 74:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/35\">",
"      Secchiero P, Zella D, Barabitskaja O, et al. Progressive and persistent downregulation of surface CXCR4 in CD4(+) T cells infected with human herpesvirus 7. Blood 1998; 92:4521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/36\">",
"      Tanaka-Taya K, Kondo T, Nakagawa N, et al. Reactivation of human herpesvirus 6 by infection of human herpesvirus 7. J Med Virol 2000; 60:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/37\">",
"      Ablashi DV, Berneman ZN, Kramarsky B, et al. Human herpesvirus-7 (HHV-7): current status. Clin Diagn Virol 1995; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/38\">",
"      Secchiero P, Berneman ZN, Gallo RC, Lusso P. Biological and molecular characteristics of human herpesvirus 7: in vitro growth optimization and development of a syncytia inhibition test. Virology 1994; 202:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/39\">",
"      Secchiero P, Bertolaso L, Casareto L, et al. Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to disregulation of cdc2 and cyclin B and polyploidization of CD4(+) T cells. Blood 1998; 92:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/40\">",
"      Gonelli A, Mirandola P, Grill V, et al. Human herpesvirus 7 infection impairs the survival/differentiation of megakaryocytic cells. Haematologica 2002; 87:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/41\">",
"      Secchiero P, Mirandola P, Zella D, et al. Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4(+) T cells. Blood 2001; 98:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/42\">",
"      Menegazzi P, Galvan M, Rotola A, et al. Temporal mapping of transcripts in human herpesvirus-7. J Gen Virol 1999; 80 ( Pt 10):2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/43\">",
"      Atedzo&eacute; BN, Menezes J, D'Addario M, et al. Modulatory effects of human herpes virus-7 on cytokine synthesis and cell proliferation in human peripheral blood mononuclear cell cultures. J Leukoc Biol 1999; 66:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/44\">",
"      Atedzoe BN, Ahmad A, Menezes J. Enhancement of natural killer cell cytotoxicity by the human herpesvirus-7 via IL-15 induction. J Immunol 1997; 159:4966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/45\">",
"      Mirandola P, Sponzilli I, Solenghi E, et al. Down-regulation of human leukocyte antigen class I and II and beta 2-microglobulin expression in human herpesvirus-7-infected cells. J Infect Dis 2006; 193:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/46\">",
"      Wyatt LS, Rodriguez WJ, Balachandran N, Frenkel N. Human herpesvirus 7: antigenic properties and prevalence in children and adults. J Virol 1991; 65:6260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/47\">",
"      Clark DA, Freeland ML, Mackie LK, et al. Prevalence of antibody to human herpesvirus 7 by age. J Infect Dis 1993; 168:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/48\">",
"      Yadav M, Nambiar S, Khoo SP, Yaacob HB. Detection of human herpesvirus 7 in salivary glands. Arch Oral Biol 1997; 42:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/49\">",
"      Ihira M, Yoshikawa T, Ohashi M, et al. Variation of human herpesvirus 7 shedding in saliva. J Infect Dis 2003; 188:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/50\">",
"      Takahashi Y, Yamada M, Nakamura J, et al. Transmission of human herpesvirus 7 through multigenerational families in the same household. Pediatr Infect Dis J 1997; 16:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/51\">",
"      Biganzoli P, Ferreyra L, Sicilia P, et al. IgG subclasses and DNA detection of HHV-6 and HHV-7 in healthy individuals. J Med Virol 2010; 82:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/52\">",
"      Stefan A, De Lillo M, Frascaroli G, et al. Development of recombinant diagnostic reagents based on pp85(U14) and p86(U11) proteins to detect the human immune response to human herpesvirus 7 infection. J Clin Microbiol 1999; 37:3980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/53\">",
"      Fujisaki H, Tanaka-Taya K, Tanabe H, et al. Detection of human herpesvirus 7 (HHV-7) DNA in breast milk by polymerase chain reaction and prevalence of HHV-7 antibody in breast-fed and bottle-fed children. J Med Virol 1998; 56:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/54\">",
"      Caserta MT, Hall CB, Schnabel K, et al. Human herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. J Infect Dis 2007; 196:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/55\">",
"      Kidd IM, Clark DA, Ait-Khaled M, et al. Measurement of human herpesvirus 7 load in peripheral blood and saliva of healthy subjects by quantitative polymerase chain reaction. J Infect Dis 1996; 174:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/56\">",
"      Gautheret-Dejean A, Dejean O, Vastel L, et al. Human herpesvirus-6 and human herpesvirus-7 in the bone marrow from healthy subjects. Transplantation 2000; 69:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/57\">",
"      Astegiano S, Costa C, Terlizzi ME, et al. Detection of human herpesvirus-7 DNA in bronchoalveolar lavage. Intervirology 2010; 53:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/58\">",
"      Lanphear BP, Hall CB, Black J, Auinger P. Risk factors for the early acquisition of human herpesvirus 6 and human herpesvirus 7 infections in children. Pediatr Infect Dis J 1998; 17:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/59\">",
"      Suga S, Yoshikawa T, Nagai T, Asano Y. Clinical features and virological findings in children with primary human herpesvirus 7 infection. Pediatrics 1997; 99:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/60\">",
"      Caserta MT, Hall CB, Schnabel K, et al. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr 1998; 133:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/61\">",
"      Tanaka K, Kondo T, Torigoe S, et al. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J Pediatr 1994; 125:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/62\">",
"      van den Berg JS, van Zeijl JH, Rotteveel JJ, et al. Neuroinvasion by human herpesvirus type 7 in a case of exanthem subitum with severe neurologic manifestations. Neurology 1999; 52:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/63\">",
"      Kawada J, Kimura H, Yoshikawa T, et al. Hemiconvulsion-hemiplegia syndrome and primary human herpesvirus 7 infection. Brain Dev 2004; 26:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/64\">",
"      Hashida T, Komura E, Yoshida M, et al. Hepatitis in association with human herpesvirus-7 infection. Pediatrics 1995; 96:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/65\">",
"      Bruns R, M&uuml;ller CE, Wiersbitzky SK, et al. Clinical presentations of infection by the human herpesvirus-7 (HHV-7). Pediatr Hematol Oncol 2000; 17:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/66\">",
"      Chiu HH, Lee CY, Lee PI, et al. Mononucleosis syndrome and coincidental human herpesvirus-7 and Epstein-Barr virus infection. Arch Dis Child 1998; 78:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/67\">",
"      Hall CB, Caserta MT, Schnabel KC, et al. Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6. J Infect Dis 2006; 193:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/68\">",
"      Clark DA, Kidd IM, Collingham KE, et al. Diagnosis of primary human herpesvirus 6 and 7 infections in febrile infants by polymerase chain reaction. Arch Dis Child 1997; 77:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/69\">",
"      Torigoe S, Kumamoto T, Koide W, et al. Clinical manifestations associated with human herpesvirus 7 infection. Arch Dis Child 1995; 72:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/70\">",
"      Torigoe S, Koide W, Yamada M, et al. Human herpesvirus 7 infection associated with central nervous system manifestations. J Pediatr 1996; 129:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/71\">",
"      Ward KN, Andrews NJ, Verity CM, et al. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child 2005; 90:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/72\">",
"      Portolani M, Cermelli C, Mirandola P, Di Luca D. Isolation of human herpesvirus 7 from an infant with febrile syndrome. J Med Virol 1995; 45:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/73\">",
"      Asano Y, Suga S, Yoshikawa T, et al. Clinical features and viral excretion in an infant with primary human herpesvirus 7 infection. Pediatrics 1995; 95:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/74\">",
"      Yoshikawa T, Ihira M, Suzuki K, et al. Invasion by human herpesvirus 6 and human herpesvirus 7 of the central nervous system in patients with neurological signs and symptoms. Arch Dis Child 2000; 83:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/75\">",
"      Cirone M, Campadelli-Fiume G, Fo&agrave;-Tomasi L, et al. Human herpesvirus 6 envelope glycoproteins B and H-L complex are undetectable on the plasma membrane of infected lymphocytes. AIDS Res Hum Retroviruses 1994; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/76\">",
"      Hidaka Y, Okada K, Kusuhara K, et al. Exanthem subitum and human herpesvirus 7 infection. Pediatr Infect Dis J 1994; 13:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/77\">",
"      Mihara T, Mutoh T, Yoshikawa T, et al. Postinfectious myeloradiculoneuropathy with cranial nerve involvements associated with human herpesvirus 7 infection. Arch Neurol 2005; 62:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/78\">",
"      Watanabe T, Sugaya M, Nakamura K, Tamaki K. Human herpesvirus 7 and pityriasis rosea. J Invest Dermatol 1999; 113:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/79\">",
"      Drago F, Ranieri E, Malaguti F, et al. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. Dermatology 1997; 195:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/80\">",
"      Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol 2005; 124:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/81\">",
"      Drago F, Malaguti F, Ranieri E, et al. Human herpes virus-like particles in pityriasis rosea lesions: an electron microscopy study. J Cutan Pathol 2002; 29:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/82\">",
"      Kempf W, Adams V, Kleinhans M, et al. Pityriasis rosea is not associated with human herpesvirus 7. Arch Dermatol 1999; 135:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/83\">",
"      De Vries HJ, van Marle J, Teunissen MB, et al. Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells. Br J Dermatol 2006; 154:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/84\">",
"      Boutolleau D, Bonduelle O, Agut H, et al. Is human herpesvirus-7 a marker or a competitor for HIV progression? AIDS 2004; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/85\">",
"      Lucht E, Brytting M, Bjerregaard L, et al. Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. Clin Infect Dis 1998; 27:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/86\">",
"      Di Luca D, Mirandola P, Ravaioli T, et al. Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. J Med Virol 1995; 45:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/87\">",
"      Kempf W, M&uuml;ller B, Maurer R, et al. Increased expression of human herpesvirus 7 in lymphoid organs of AIDS patients. J Clin Virol 2000; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/88\">",
"      Boutolleau D, Bonduelle O, Sabard A, et al. Detection of human herpesvirus 7 DNA in peripheral blood reflects mainly CD4+ cell count in patients infected with HIV. J Med Virol 2005; 76:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/89\">",
"      Tong CY, Bakran A, Williams H, et al. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 2000; 70:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/90\">",
"      Kidd IM, Clark DA, Sabin CA, et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000; 69:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/91\">",
"      Chapenko S, Folkmane I, Ziedina I, et al. Association of HHV-6 and HHV-7 reactivation with the development of chronic allograft nephropathy. J Clin Virol 2009; 46:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/92\">",
"      Chan PK, Peiris JS, Yuen KY, et al. Human herpesvirus-6 and human herpesvirus-7 infections in bone marrow transplant recipients. J Med Virol 1997; 53:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/93\">",
"      Zawilinska B, Kopec J, Szostek S, et al. Lymphotropic herpesvirus DNA detection in patients with active CMV infection - a possible role in the course of CMV infection after hematopoietic stem cell transplantation. Med Sci Monit 2011; 17:CR432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/94\">",
"      Maeda Y, Teshima T, Yamada M, et al. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Br J Haematol 1999; 105:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/95\">",
"      Chan PK, Li CK, Chik KW, et al. Risk factors and clinical consequences of human herpesvirus 7 infection in paediatric haematopoietic stem cell transplant recipients. J Med Virol 2004; 72:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/96\">",
"      Savolainen H, Lautenschlager I, Piiparinen H, et al. Human herpesvirus-6 and -7 in pediatric stem cell transplantation. Pediatr Blood Cancer 2005; 45:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/97\">",
"      Khanani M, Al-Ahmari A, Tellier R, et al. Human herpesvirus 7 in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer 2007; 48:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/98\">",
"      Ward KN, White RP, Mackinnon S, Hanna M. Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. Bone Marrow Transplant 2002; 30:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/99\">",
"      Yoshikawa T, Yoshida J, Hamaguchi M, et al. Human herpesvirus 7-associated meningitis and optic neuritis in a patient after allogeneic stem cell transplantation. J Med Virol 2003; 70:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/100\">",
"      Chan PK, Chik KW, To KF, et al. Case report: human herpesvirus 7 associated fatal encephalitis in a peripheral blood stem cell transplant recipient. J Med Virol 2002; 66:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/101\">",
"      Boutolleau D, Fernandez C, Andr&eacute; E, et al. Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis 2003; 187:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/102\">",
"      Moschettini D, De Milito A, Catucci M, et al. Detection of human herpesviruses 6 and 7 in heart transplant recipients by a multiplex polymerase chain reaction method. Eur J Clin Microbiol Infect Dis 1998; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/103\">",
"      Pascher A, Klupp J, Schulz RJ, et al. CMV, EBV, HHV6, and HHV7 infections after intestinal transplantation without specific antiviral prophylaxis. Transplant Proc 2004; 36:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/104\">",
"      Griffiths PD, Ait-Khaled M, Bearcroft CP, et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/105\">",
"      Feldstein AE, Razonable RR, Boyce TG, et al. Prevalence and clinical significance of human herpesviruses 6 and 7 active infection in pediatric liver transplant patients. Pediatr Transplant 2003; 7:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/106\">",
"      Peigo MF, Thomasini RL, Puglia AL, et al. Human herpesvirus-7 in Brazilian liver transplant recipients: a follow-up comparison between molecular and immunological assays. Transpl Infect Dis 2009; 11:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/107\">",
"      H&auml;rm&auml; M, H&ouml;ckerstedt K, Lyytik&auml;inen O, Lautenschlager I. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol 2006; 78:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/108\">",
"      Sampaio AM, Thomasini RL, Guardia AC, et al. Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in adult liver transplant recipients: diagnosis based on antigenemia. Transplant Proc 2011; 43:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/109\">",
"      Secchiero P, Bonino LD, Lusso P, et al. Human herpesvirus type 7 in Hodgkin's disease. Br J Haematol 1998; 101:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/110\">",
"      Berneman ZN, Torelli G, Luppi M, Jarrett RF. Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy. Ann Hematol 1998; 77:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/111\">",
"      Nagore E, Ledesma E, Collado C, et al. Detection of Epstein-Barr virus and human herpesvirus 7 and 8 genomes in primary cutaneous T- and B-cell lymphomas. Br J Dermatol 2000; 143:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/112\">",
"      Ongr&aacute;di J, Rajda C, Mar&oacute;di CL, et al. A pilot study on the antibodies to HHV-6 variants and HHV-7 in CSF of MS patients. J Neurovirol 1999; 5:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/113\">",
"      Mirandola P, Stefan A, Brambilla E, et al. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology 1999; 53:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/114\">",
"      Taus C, Pucci E, Cartechini E, et al. Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis. Acta Neurol Scand 2000; 101:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/115\">",
"      Opsahl ML, Kennedy PG. Investigating the presence of human herpesvirus 7 and 8 in multiple sclerosis and normal control brain tissue. J Neurol Sci 2006; 240:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/116\">",
"      Soden JS, Narkewicz MR, Haas JE, Sokol RJ. Hepatic veno-occlusive disease and human herpes virus 7 infection in primary agammaglobulinemia. J Pediatr 2009; 154:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/117\">",
"      Gibson CS, MacLennan AH, Goldwater PN, et al. Neurotropic viruses and cerebral palsy: population based case-control study. BMJ 2006; 332:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/118\">",
"      Yoshikawa T, Ihira M, Taguchi H, et al. Analysis of shedding of 3 beta-herpesviruses in saliva from patients with connective tissue diseases. J Infect Dis 2005; 192:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/119\">",
"      Thomasini RL, Bonon SH, Durante P, Costa SC. Correlation of cytomegalovirus and human herpesvirus 7 with CD3+ and CD3+ CD4+ cells in chronic periodontitis patients. J Periodontal Res 2012; 47:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/120\">",
"      Leite JL, Bufalo NE, Santos RB, et al. Herpesvirus type 7 infection may play an important role in individuals with a genetic profile of susceptibility to Graves' disease. Eur J Endocrinol 2010; 162:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/121\">",
"      Huang LM, Lee CY, Liu MY, Lee PI. Primary infections of human herpesvirus-7 and herpesvirus-6: a comparative, longitudinal study up to 6 years of age. Acta Paediatr 1997; 86:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/122\">",
"      Ward KN, Couto Parada X, Passas J, Thiruchelvam AD. Evaluation of the specificity and sensitivity of indirect immunofluorescence tests for IgG to human herpesviruses-6 and -7. J Virol Methods 2002; 106:107.",
"     </a>",
"    </li>",
"    <li>",
"     Canada Population and Public Health Branch. Expert working group on HHV-6 and 7 laboratory diagnosis and testing. Canada Communicable Disease Report &ndash; Supplement 2000; 26S4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/124\">",
"      Franti M, Aubin JT, De Saint-Maur G, et al. Immune reactivity of human sera to the glycoprotein B of human herpesvirus 7. J Clin Microbiol 2002; 40:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/125\">",
"      Kidd IM, Clark DA, Bremner JA, et al. A multiplex PCR assay for the simultaneous detection of human herpesvirus 6 and human herpesvirus 7, with typing of HHV-6 by enzyme cleavage of PCR products. J Virol Methods 1998; 70:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/126\">",
"      Black JB, Burns DA, Goldsmith CS, et al. Biologic properties of human herpesvirus 7 strain SB. Virus Res 1997; 52:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/127\">",
"      Hudnall SD, Chen T, Tyring SK. Species identification of all eight human herpesviruses with a single nested PCR assay. J Virol Methods 2004; 116:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/128\">",
"      Safronetz D, Humar A, Tipples GA. Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. J Virol Methods 2003; 112:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/129\">",
"      Fernandez C, Boutolleau D, Manichanh C, et al. Quantitation of HHV-7 genome by real-time polymerase chain reaction assay using MGB probe technology. J Virol Methods 2002; 106:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/130\">",
"      Bergallo M, Costa C, Terlizzi ME, et al. Development of a LUX real-time PCR for the detection and quantification of human herpesvirus 7. Can J Microbiol 2009; 55:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/131\">",
"      Zhang Y, Schols D, De Clercq E. Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Res 1999; 43:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/132\">",
"      Yoshida M, Yamada M, Tsukazaki T, et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/133\">",
"      Vermeire K, Zhang Y, Princen K, et al. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002; 302:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/134\">",
"      Brennan DC, Storch GA, Singer GG, et al. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. J Infect Dis 2000; 181:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14201/abstract/135\">",
"      Galarraga MC, Gomez E, de O&ntilde;a M, et al. Influence of ganciclovir prophylaxis on citomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients. Transplant Proc 2005; 37:2124.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8309 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14201=[""].join("\n");
var outline_f13_55_14201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11242920\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cell tropism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Viral entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effects on cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pityriasis rosea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HHV-7 and AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other possible disease associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11242920\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28982?source=related_link\">",
"      Roseola infantum (exanthem subitum)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_55_14202="Clinical manifestations and treatment of Epstein-Barr virus infection";
var content_f13_55_14202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and treatment of Epstein-Barr virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14202/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14202/contributors\">",
"     John L Sullivan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14202/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14202/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14202/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/55/14202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/55/14202/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/55/14202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) is a widely disseminated herpesvirus that is spread by intimate contact between susceptible persons and asymptomatic EBV shedders. EBV is the primary agent of infectious mononucleosis (IM), persists asymptomatically for life in nearly all adults, and is associated with the development of B cell lymphomas, T cell lymphomas, Hodgkin lymphoma and nasopharyngeal carcinomas in certain patients. Reactivation disease is not a prominent issue with EBV, in contrast to other common herpesviruses, but it has been associated with an aggressive lymphoproliferative disorder in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of EBV infections will be reviewed here. The diagnosis of EBV as pertains to infectious mononucleosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2004940\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of primary EBV infections throughout the world are subclinical and inapparent. Antibodies to EBV have been demonstrated in all population groups with a worldwide distribution; approximately 90 to 95 percent of adults are EBV-seropositive. The host range of EBV is restricted to humans and certain subhuman primates including squirrel monkeys and cotton top marmosets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2004947\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other members of the herpesvirus family, EBV has a latency phase. The host cells for the organism in humans are limited to B lymphocytes, T lymphocytes, epithelial cells and myocytes. Unlike herpes simplex (HSV) or cytomegalovirus (CMV), EBV is capable of transforming B cells but does not routinely display a cytopathic effect. A detailed discussion of the virology of EBV is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV can cause a number of primary infections, can lead to complications, and can induce a variety of malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2005083\">",
"    <span class=\"h2\">",
"     Acute infectious mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious mononucleosis (IM) is the best known acute clinical manifestation of EBV. IM often begins with malaise, headache, and low-grade fever before development of the more specific signs of tonsillitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharyngitis, cervical lymph node enlargement and tenderness, and moderate to high fever [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/3\">",
"     3",
"    </a>",
"    ]. Affected patients usually have peripheral blood lymphocytosis, composed in large measure of atypical lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef55986 \" href=\"UTD.htm?1/24/1410\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lymphadenopathy characteristically is symmetric and involves the posterior cervical chain more than the anterior chain. Tonsillar exudate is a frequent component of the pharyngitis; the exudate can have a white, gray-green, or necrotic appearance.",
"   </p>",
"   <p>",
"    Severe fatigue may be prominent, while other less common findings include palatal petechiae, periorbital or palpebral edema, and maculopapular or morbilliform rashes. Nausea, vomiting, and anorexia are frequent in patients with IM, probably reflecting the mild hepatitis encountered in about 90 percent of infected individuals. Splenomegaly occurs in as many as 50 percent of patients, but jaundice and hepatomegaly are uncommon.",
"   </p>",
"   <p>",
"    Most patients with IM caused by EBV have prominent pharyngeal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/4\">",
"     4",
"    </a>",
"    ]. There are, however, several other forms of the illness. Some individuals with IM present with the so-called &ldquo;glandular&rdquo; form of the disease in which lymph node enlargement is out of proportion to the pharyngeal symptoms; others develop a systemic form of the infection in which fever and fatigue predominate, while lymphadenopathy and pharyngitis are mild or absent. Some patients have hepatitis in the absence of other typical features of IM.",
"   </p>",
"   <p>",
"    Most individuals with primary EBV infection recover uneventfully and develop a high degree of durable immunity. Acute symptoms resolve in one to two weeks, but fatigue often persists for months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2005184\">",
"    <span class=\"h2\">",
"     Primary EBV infection in infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary EBV infections in young infants and children are common and frequently asymptomatic. When symptoms do occur, a variety of manifestations have been observed, including otitis media, diarrhea, abdominal complaints, upper respiratory infection, and IM [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, one series reported 32 children younger than 4 years of age with IM, selected from a population of 200 children by review of blood smears (more than 50 percent mononuclear cells and more than 10 percent atypical lymphocytes) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/6\">",
"     6",
"    </a>",
"    ]. The majority of these children had clinical evidence compatible with IM (significant cervical adenopathy and tonsillar pharyngitis); respiratory symptoms were frequently prominent, especially in young infants.",
"   </p>",
"   <p>",
"    Children can have symptomatic primary EBV infection without the production of heterophile antibodies; as a result, EBV-specific serologic studies are required to establish the diagnosis. In the above series of 32 children, interpretation of the results of serology was most problematic in children below the age of two years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The heterophile test was particularly insensitive (25 percent positive for ages 10 to 24 months versus 75 percent for ages 24 to 28 months).",
"     </li>",
"     <li>",
"      Anti-viral capsid antigen (VCA) IgM was less frequently positive in infants (60 percent compared with 100 percent in older children and young adults); in addition, peak titers of VCA antibody were lower, and the development of antibodies to early antigen was less common in infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the reduction in antibody production, young infants can mount an EBV-specific cytotoxic T lymphocyte response during acute EBV infection and that the latent proteins recognized are identical to those recognized by young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Congenital and perinatal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine infection with EBV is rare because fewer than 5 percent of pregnant women are susceptible to the virus. In addition, prospective studies of susceptible (ie, seronegative) women have not found evidence of congenital abnormalities among infants of women who did develop primary EBV infection during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/8\">",
"     8",
"    </a>",
"    ]. While isolated cases of infants with some evidence for EBV infection and congenital anomalies (biliary atresia, congenital heart disease, hypotonia, micrognathia, cataracts and thrombocytopenia) have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/9\">",
"     9",
"    </a>",
"    ], the evidence argues against EBV as a significant cause of congenital infection. Specifically, no evidence of EBV infection has been demonstrated in large studies of children with congenital anomalies or in cord blood samples [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV can affect virtually any organ system and has been associated with such diverse disease manifestations as pneumonia, myocarditis, pancreatitis, mesenteric adenitis, myositis, glomerulonephritis, and genital ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/11\">",
"     11",
"    </a>",
"    ]. A large number of other manifestations have been associated with primary EBV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic syndromes can include Guillain-Barr&eacute; syndrome, facial nerve palsy, meningoencephalitis, aseptic meningitis, transverse myelitis, peripheral neuritis, and optic neuritis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hematologic abnormalities can include hemolytic anemia, thrombocytopenia, aplastic anemia, thrombotic thrombocytopenic",
"      <span class=\"nowrap\">",
"       purpura/hemolytic-uremic",
"      </span>",
"      syndrome, and disseminated intravascular coagulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13966774\">",
"    <span class=\"h2\">",
"     Chronic EBV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic EBV infection is a rare disorder characterized by ongoing symptoms of an infectious mononucleosis syndrome with active viremia. This entity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV infection is associated with a number of acute complications and, in certain hosts, more delayed effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the more common complications of IM is a morbilliform rash following the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , and to a lesser extent, penicillin. The incidence initially was reported to be as high as 70 to 90 percent but is probably lower [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/13\">",
"     13",
"    </a>",
"    ]. The mechanism responsible for this rash is not understood but has been thought to involve circulating antibodies to ampicillin. Development of this rash during IM does not appear to presage an ampicillin allergy; patients have subsequently tolerated ampicillin without an adverse reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Oral hairy leukoplakia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another EBV-mediated mucocutaneous manifestation is oral hairy leukoplakia (OHL), which is an unusual disease of the lingual squamous epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/14\">",
"     14",
"    </a>",
"    ]. OHL generally affects the lateral portions of the tongue, although the floor of the mouth, the palate, or the buccal mucosa may also be involved. The lesions are described as white corrugated painless plaques that, unlike candida, cannot be scraped from the surface to which they adhere (",
"    <a class=\"graphic graphic_picture graphicRef72106 \" href=\"UTD.htm?34/9/34961\">",
"     picture 2",
"    </a>",
"    ). They are not generally associated with fever.",
"   </p>",
"   <p>",
"    The OHL lesions appear to be relatively specific for HIV infection, since they are only rarely observed in patients with other immunodeficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The use of highly active antiretroviral therapy appears to have reduced the incidence of OHL [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OHL is associated with intense EBV replication and the action of EBV-encoded proteins such as latent membrane protein-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, studies in which EBV replication has been suppressed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    have demonstrated persistent, nonproductive EBV infection and continued EBV entry from the blood into the tongue [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/18\">",
"     18",
"    </a>",
"    ]. These observations suggest a role for entry, persistence, and reactivation of oral epithelial EBV in the pathogenesis of OHL.",
"   </p>",
"   <p>",
"    OHL is not considered a premalignant lesion, being unlikely to progress to squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/14\">",
"     14",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , and topical podophyllin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    has been reported, although therapy is usually not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Splenic rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic rupture is a rare but potentially life-threatening complication of IM, estimated to occur in between one and two cases per thousand [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Almost all cases have been in males. A number of observations about splenic rupture have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic rupture is often the first symptom of IM that brings the patient to medical attention; it is spontaneous in more than one-half of reported cases, with no history of specific injury.",
"     </li>",
"     <li>",
"      For those patients who had previously been seen by a physician, the spleen had not been palpably enlarged in approximately one-half despite its two- to threefold increase in size (based upon surgical evaluation).",
"     </li>",
"     <li>",
"      Rupture has occurred between the fourth and twenty-first day of symptomatic illness, and has not correlated with the clinical severity of IM or with laboratory findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite its life-threatening potential, fatality from this complication is rare. The management of splenic rupture is similar to other forms of splenic injury. Nonoperative treatment with intensive supportive care and splenic preservation has been successfully carried out in some cases, while others require splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction of the upper airway due to massive lymphoid hyperplasia and mucosal edema is an uncommon but potentially fatal complication of IM. Severe obstruction can be successfully treated by tracheotomy or endotracheal intubation. The use of corticosteroids to reduce pharyngeal edema and lymphoid hypertrophy is advocated for individuals with incipient obstruction (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Corticosteroids'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lymphoproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV infection is associated with a variety of lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hemophagocytic lymphohistiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV is one of the recognized initiating causes of hemophagocytic lymphohistiocytosis (HLH), a potentially fatal genetic disorder characterized pathologically by generalized histiocytic proliferation and hemophagocytosis (",
"    <a class=\"graphic graphic_picture graphicRef81067 \" href=\"UTD.htm?17/30/17890\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with this unusual syndrome present with fever, generalized lymphadenopathy, hepatosplenomegaly, hepatitis, pancytopenia and coagulopathy. T cell proliferation is a primary feature of HLH. The pathogenesis, diagnosis and treatment of this disorder are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lymphomatoid granulomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomatoid granulomatosis is an angiodestructive disorder of the lymphoid system, which has been associated with EBV infection. In the majority of cases, EBV infected B cells are present, and the B cell proliferation is clonal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Patients often have evidence of immunodeficiency including congenital and acquired conditions such as HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/26\">",
"     26",
"    </a>",
"    ]. Clinical features include fever, cough, malaise, weight loss, with involvement of lung, kidney, liver, skin and subcutaneous tissue, and the central nervous system (CNS) with typical histologic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. It appears to arise from EBV-infected B cells and affected patients may respond to interferon alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link\">",
"     \"Pulmonary lymphomatoid granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     X-linked lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked lymphoproliferative (XLP) disease is characterized by a selective immunodeficiency to EBV, manifested by severe or fatal IM and acquired immunodeficiency. Two genetic defects that cause XLP have been identified. XLP1, the more common of the two forms, is due to a defect in a gene (ie, SH2D1A) that encodes a protein, which plays an important role in signal transduction pathways in T lymphocytes. This mutation prevents normal activation-induced cell death, resulting in the uncontrolled CD8 T cell proliferation that is observed in patients with XLP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/31\">",
"     31",
"    </a>",
"    ]. XLP2 is due to a defect in the XIAP gene that encodes the X-linked inhibitor of apoptosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33384?source=see_link\">",
"     \"X-linked lymphoproliferative disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Posttransplant lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV is associated with the majority of cases of posttransplant lymphoproliferative disease (PTLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/32\">",
"     32",
"    </a>",
"    ]. The abnormalities range from benign polyclonal B cell proliferation to malignant B cell lymphoma. The frequency of PTLD is related to the degree and type of immunosuppression and is most common in EBV-negative recipients who develop primary EBV infection, usually from a graft from an EBV-positive donor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV is a transforming virus and has been causally linked to a variety of malignancies in addition to lymphomas in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/22\">",
"     22",
"    </a>",
"    ]. These include Burkitt lymphoma, tumors in HIV-infected patients, Hodgkin lymphoma, nasopharyngeal and other head and neck carcinomas, and T cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=see_link\">",
"     \"The role of Epstein-Barr virus in Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29529?source=see_link\">",
"     \"Overview of the pathobiology of the non-Hodgkin lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Burkitt lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burkitt lymphoma (BL), which is characteristically localized in the jaw, is the most common childhood malignancy in equatorial Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/34\">",
"     34",
"    </a>",
"    ]. More than 95 percent of African children are infected with EBV by age three, whereas, in affluent countries, primary infection is often delayed until adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor cells from areas where BL is endemic contain copies of the EBV genome more frequently than sporadic cases of BL from areas of low incidence (&gt;95 percent versus 15 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Analysis of the EBV genome terminal repeat frequency in endemic Burkitt lymphomas has demonstrated that the tumors originate in the lineage of a single EBV-infected B cell [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malignant cells obtained from fresh tumor biopsies consistently display a homogeneous surface phenotype including the pan B cell marker CD20, the common acute lymphoblastic leukemia antigen (CALLA, CD10), and the BL-associated antigen (CD77) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/41\">",
"     41",
"    </a>",
"    ]. These cells do not express the B cell activation antigens CD23, CD30, CD39, and CD70 or the cell adhesion molecules LFA-1",
"    <span class=\"nowrap\">",
"     (CD11a/18),",
"    </span>",
"    ICAM-1 (CD54), and LFA-3 (CD58) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Fresh BL tumor cells retain a resting B cell phenotype and typically express only EBNA-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Immunophenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The internal Gly-Ala repeat of EBNA-1 inhibits antigen processing of peptides recognized by EBV specific cytotoxic lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/45\">",
"     45",
"    </a>",
"    ]. This observation, along with reduced expression of MHC class I antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/46\">",
"     46",
"    </a>",
"    ] and the lack of adhesion molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], probably contributes to the ability of these cells to escape T cell-mediated destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Effect of coinfection with malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria and EBV infection are considered cofactors in the genesis of Burkitt lymphoma. An epidemiologic link is suggested by the number of endemic cases that occur in discrete geographic climates located along the malaria belt across Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/47\">",
"     47",
"    </a>",
"    ]. Various hypotheses have been proposed to explain the role of malaria in pathogenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute malaria infection may increase the EBV viremia set point. One study of quantitative EBV genome loads within peripheral blood mononuclear cells among 57 EBV-seropositive Gambian children suggested that acute malarial infection was associated with a sixfold increase in viremia compared to age-matched EBV-seropositive controls without malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malaria may provide a chronic stimulus for proliferation of B lymphocytes, some of which carry latent EBV. In one study of 43 children with malaria, anti-malarial therapy led to a significant decline in EBV DNA plasma levels by day 14 of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/35\">",
"       35",
"      </a>",
"      ]. The clearance of circulating EBV after antimalarial treatment suggests a direct relationship between active malaria infection and reactivation of EBV.",
"     </li>",
"     <li>",
"      Alternatively, malaria infection may impair EBV-specific T cell immunity and lead to loss of viral control [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/49\">",
"       49",
"      </a>",
"      ]. One study in Kenya demonstrated that children (1 to 14 years of age) living in malaria-endemic regions had significantly fewer EBV-specific cytotoxic T-cell responses than did those living in areas with unstable malaria transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/50\">",
"       50",
"      </a>",
"      ]. Evidence of suppression of EBV-related immunity was demonstrated in patients up to nine years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings correlate with epidemiologic data, which show a peak incidence of Burkitt lymphoma in children ranging in age from 5 to 9 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Malignancies and HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among HIV-infected patients, EBV infection has been associated with non-Hodgkin lymphoma and, in children, smooth muscle tumors. Oral hairy leukopenia is another EBV-induced manifestation in HIV-infected patients but is not considered to represent a premalignant lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/14\">",
"     14",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H8\">",
"     'Rash'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-Hodgkin lymphoma &mdash; Non-Hodgkin lymphomas (NHL) occur approximately 60 to 100 times more frequently than expected in patients infected with the human immunodeficiency virus (HIV) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. These tumors are often associated with EBV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. A study conducted in Los Angeles county from 1984 to 1992 showed that EBV was associated with 39 of 59 (66 percent) HIV-related systemic lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/53\">",
"       53",
"      </a>",
"      ]. Analysis of EBV terminal repeats in these lymphomas again confirmed their monoclonal origin, and c-myc rearrangements were noted in 40 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link&amp;anchor=H10#H10\">",
"       \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\", section on 'Diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Given the profound immune defects in HIV-infected patients, along with the known role of cytotoxic lymphocytes in controlling EBV-induced proliferation, it is not surprising that the number of EBV-infected B cells in the peripheral blood of HIV-infected patients is higher than the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/55\">",
"       55",
"      </a>",
"      ]. Furthermore, the development of lymphoma may be preceded by a decline in EBV-specific cytotoxic lymphocytes, suggesting that failing EBV control may be an important pathogenetic step [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      HIV associated NHL, usually of B cell origin, is a relatively late manifestation of HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/51,57\">",
"       51,57",
"      </a>",
"      ]. For unknown reasons, a much higher percentage of EBV-associated NHLs in HIV-infected patients present as primary CNS lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=see_link\">",
"       \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smooth muscle tumors &mdash; Children infected with HIV appear to have a higher propensity for developing smooth muscle tumors (leiomyomas and leiomyosarcomas), which are ordinarily very rare [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. EBV probably plays a pathogenic role in the development of these tumors as illustrated by the following observations:",
"     </li>",
"     <li>",
"      EBV can infect smooth muscle cells in HIV-infected individuals, and high levels of EBV genomes have been found in tumor tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Smooth-muscle tumors containing clonal EBV developed in three children after liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV genomic DNA was first reported in tissue specimens from patients with Hodgkin lymphoma (HL) in 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/61\">",
"     61",
"    </a>",
"    ]. The finding that the malignant cells in HL, including the characteristic Reed-Sternberg cells, contain the EBV genome in up to 50 percent of \"Western\" cases supports a pathogenic role for EBV in this malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/62\">",
"     62",
"    </a>",
"    ]. One retrospective study of 34 patients also demonstrated a strong association between EBV infection and HL-associated hemophagocytic syndrome; 94 percent of tumor cells from nodal and extranodal tissues had EBV antigens as measured by immunoperoxidase techniques and in situ hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=see_link\">",
"     \"The role of Epstein-Barr virus in Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While Burkitt lymphoma has distinct geographic predilections, it appears that the epidemiology of HL associated with EBV is more complex. In a number of South American countries, a high percentage of cases of classical HL have been found to contain EBV transcripts within Reed-Sternberg cells (94 percent in Peru) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/64\">",
"     64",
"    </a>",
"    ]. However, geography does not appear to be the critical determinant for the prevalence of EBV-associated HL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study comparing cases in Kenya and Japan, EBV-encoded RNA (EBER-1) was detected in 79 and 59 percent of cases, respectively, and in 100 percent of patients younger than the age of 9 years in both countries [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparing EBV-associated cases of HL in Brazil and the United States adjusting for histiotype, EBV was linked to Reed-Sternberg cells and their variants and to age &le;10 years, not to geography [",
"      <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Healthy western populations are infected with predominantly type 1 EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/67\">",
"     67",
"    </a>",
"    ], and not surprisingly, the majority of EBV detected in HL is type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/68\">",
"     68",
"    </a>",
"    ]. In contrast, there is an almost equal frequency of type 1 and type 2 EBV in HIV-associated NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/69\">",
"     69",
"    </a>",
"    ] and endemic Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of EBV latency in HL most closely resembles the type-II latency described in nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/71\">",
"     71",
"    </a>",
"    ]. EBER-1 and latency membrane protein- (LMP) 1 are the two EBV markers most often expressed in HL [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nasopharyngeal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is relatively rare in most populations. However, it is one of the most common cancers in southern China with age-adjusted incidence rates of up to 55 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/73\">",
"     73",
"    </a>",
"    ]. In contrast to Burkitt lymphoma, the association of EBV with nasopharyngeal carcinoma is highly consistent in both low- and high-incidence areas and EBV is present in every anaplastic nasopharyngeal carcinoma cell [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"     \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large body of evidence supports the role of EBV as the primary etiologic agent in the pathogenesis of nasopharyngeal carcinoma, although the great majority of EBV-infected patients in China do not develop this tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/75\">",
"     75",
"    </a>",
"    ]. The presence of a single clonal form of EBV in preinvasive lesions, such as nasopharyngeal dysplasia or carcinoma in situ, indicates that EBV-induced cellular proliferation precedes invasion of these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasopharyngeal carcinoma cells express a specific subgroup of EBV latent proteins, including EBNA-1 and two integral membrane proteins, LMP-1 and LMP-2, along with the BamHI-A fragment of the EBV genome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In light of the molecular link between LMP-1 and cell growth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/79\">",
"     79",
"    </a>",
"    ], the universal presence of LMP-1 in nasopharyngeal carcinoma makes it a likely prerequisite for this multistep neoplastic transformation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells are also susceptible to EBV infection as illustrated in studies of EBV-infected tonsillar tissues in individuals with IM [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/80\">",
"     80",
"    </a>",
"    ]. This observation is consistent with the description of T cell lymphomas in individuals with chronic EBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/81\">",
"     81",
"    </a>",
"    ]. The expression of EBV latent genes EBNA-1, LMP-1, LMP-2 has been demonstrated in EBV-associated peripheral T cell lymphomas similar to the expression in nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fulminant form of T cell lymphoma has been described following acute EBV infection. One series of five patients described a clinical illness characterized by fever, hepatosplenomegaly and pancytopenia; significant erythrophagocytosis was detected in tissue specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/83\">",
"     83",
"    </a>",
"    ]. The disease was uniformly fatal. Molecular analysis demonstrated clonal proliferation of otherwise morphologically unimpressive T cells. Serologic markers for EBV in serum were variable in these cases, but EBER1 of EBV was present in the majority of cells by in situ hybridization and polymerase chain reaction revealed clonal gene rearrangements in all but one",
"    <span class=\"nowrap\">",
"     case.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nasal/nasal type angiocentric lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal/nasal",
"    type angiocentric lymphomas are rare diseases that are endemic to Asian countries as well as Central and South America [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. The sites of involvement include the nasal septum, palate, GI tract, and less commonly skin, testis and peripheral nerve. EBV is found in virtually all cases in the neoplastic cells. Although originally thought to be T cells, the malignant cells express CD2, CD56 but lack CD3 and T cell receptor gene rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/87\">",
"     87",
"    </a>",
"    ]. Thus, these tumors are probably of NK cell origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV infection is suspected when patients present with typical symptoms, and supportive evidence of infection is derived from the peripheral blood smear and antibody studies.",
"   </p>",
"   <p>",
"    The diagnosis of EBV is discussed primarily in the context of infectious mononucleosis, and a detailed discussion of the diagnosis of this disorder is found separately. Although this topic is devoted to patients with infectious mononucleosis, patients with other manifestations of suspected EBV infection can also be diagnosed using these serologic and virologic methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link&amp;anchor=H18#H18\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary EBV infections rarely require more than supportive therapy. Even in clinical situations where an antiviral or immunomodulatory treatment would be desirable, it is not clear that EBV responds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment for individuals with IM and other manifestations of primary EBV disease is supportive care.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs are recommended for the treatment of fever, throat discomfort, and malaise. Provision of adequate fluids and nutrition is also appropriate. Although getting adequate rest is prudent, bed rest is unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of corticosteroids in the treatment of EBV-induced IM has been controversial. In a multicenter, placebo-controlled study of 94 patients with acute IM, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    reduced oropharyngeal shedding of the virus but did not affect the duration of symptoms or lead to an earlier return to school or work [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/88\">",
"     88",
"    </a>",
"    ]. Studies focusing on steroid therapy alone have been imperfect but do suggest that these agents induce a modest improvement with diminishment of lymphoid and mucosal swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend corticosteroid therapy for routine cases of IM since it is generally a self-limited illness and there are theoretical concerns about immunomodulation of a virus with transforming potential. However, a trial of corticosteroids is warranted in individuals with impending airway obstruction (manifested clinically by difficulty breathing or dyspnea in the recumbent position) and should be considered in those suffering from severe overwhelming life-threatening infection (eg, liver failure) or other severe complications such as aplastic anemia. Data supporting the benefit of corticosteroids in the last two settings are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Antiviral treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is a nucleoside analogue that inhibits permissive EBV infection through inhibition of EBV DNA polymerase but has no effect on latent infection. Specific therapy of acute EBV infections with intravenous and oral formulations of acyclovir has been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/88,90\">",
"     88,90",
"    </a>",
"    ]. As noted above, while short-term suppression of viral shedding can be demonstrated, significant clinical benefit has been lacking. A meta-analysis of five randomized controlled trials of acyclovir in the treatment of acute IM, including two trials of intravenous therapy in patients with severe disease, also failed to show a clinical benefit compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/91\">",
"     91",
"    </a>",
"    ]. Oropharyngeal shedding of the virus decreased significantly by the end of therapy in the groups receiving acyclovir but this difference was no longer observed three weeks after therapy was discontinued. These results are not surprising since there is little evidence that ongoing viral replication plays a role in the symptomatic phase of EBV-induced mononucleosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the majority of the EBV-associated malignancies in which the stage of the virus life cycle has been characterized, there is little evidence for permissive (lytic) infection. Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is only effective in inhibiting replication of linear EBV DNA there is little to be gained by its use in diseases associated with latent infection. There is anecdotal support for the use of acyclovir in EBV-induced hemophagocytic lymphohistiocytosis where evidence of replicating EBV was demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal use of other agents such as interleukin-2, interferon alfa, and intravenous immunoglobulins in EBV-associated diseases have been reported. No clear benefits of such modalities have been demonstrated at this time with the possible exceptions of lymphomatoid granulomatosis and posttransplant lymphoproliferative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Active immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large body of evidence implicating EBV in the etiology of a variety of human neoplasms has made the prospect of developing a viral-based vaccine effective against human cancers very appealing.",
"    <span class=\"nowrap\">",
"     Gp350/220",
"    </span>",
"    is one of the most abundant viral proteins present in lytically infected cell plasma membranes and the most abundant protein on the outer surface of the virus coat; it also binds to the CD21 receptor on the B cell which is responsible for the initiation of infection. In addition, most of the human EBV neutralizing antibody response is directed against",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. For these reasons,",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    is the major EBV lytic-cycle gene being pursued in the development of a subunit vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animal studies, immunization with partially purified",
"    <span class=\"nowrap\">",
"     gp350/220",
"    </span>",
"    antigen induces EBV-neutralizing antibody, which protects a portion of cottontop tamarins against a normally lethal, lymphoma-producing challenge with EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/94\">",
"     94",
"    </a>",
"    ]. A recombinant EBV subunit glycoprotein 350 vaccine has been studied in four clinical trials. The vaccine was shown to be safe and immunogenic; although it did not prevent EBV infection, the vaccine reduced clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/55/14202/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/11/176?source=see_link\">",
"       \"Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2004981\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epstein-Barr virus (EBV) is a widely disseminated herpesvirus that is spread by close contact between susceptible persons and asymptomatic EBV shedders. EBV is the primary agent of infectious mononucleosis (IM) and is associated with the development of B cell lymphoma, T cell lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of primary EBV infections throughout the world are subclinical and inapparent. (See",
"      <a class=\"local\" href=\"#H2004940\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infectious mononucleosis (IM) usually begins with malaise, headache, and low-grade fever before onset of more specific signs of the infection, such as pharyngitis and cervical lymph node enlargement. Patients usually have a peripheral blood lymphocytosis, with a significant proportion of atypical lymphocytes. (See",
"      <a class=\"local\" href=\"#H2005083\">",
"       'Acute infectious mononucleosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary EBV infections in young infants and children are common but are frequently asymptomatic. When symptoms do occur, a variety of manifestations have been observed, including otitis media, diarrhea, abdominal complaints, upper respiratory infection, and symptoms and signs consistent with infectious mononucleosis. (See",
"      <a class=\"local\" href=\"#H2005184\">",
"       'Primary EBV infection in infants and children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrauterine infection with EBV is rare because fewer than 5 percent of pregnant women are susceptible to the virus. In addition, congenital abnormalities have not been documented among infants of women who did develop primary EBV infection during pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Congenital and perinatal infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Morbilliform rashes sometimes follow the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      in a patient with infectious mononucleosis. The mechanism responsible for this rash is not understood but has been thought to involve circulating antibodies to ampicillin. Development of this rash during IM does not appear to presage an ampicillin allergy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral hairy leukoplakia (OHL) is described as white corrugated painless plaques that usually affect the lateral portions of the tongue among patients with advanced HIV infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oral hairy leukoplakia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splenic rupture is a rare but potentially life-threatening complication of IM and may be the first symptom of infectious mononucleosis that brings the patient to medical attention. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Splenic rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of treatment for patients with infectious mononucleosis and other manifestations of primary EBV disease is supportive care.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      or nonsteroidal antiinflammatory drugs are recommended for the treatment of fever, throat discomfort, and malaise. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/1\">",
"      Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev 2011; 24:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/2\">",
"      Miller G, Shope T, Lisco H, et al. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A 1972; 69:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/3\">",
"      Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med 2010; 362:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/4\">",
"      EVANS AS. Infectious mononucleosis in University of Wisconsin students. Report of a five-year investigation. Am J Hyg 1960; 71:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/5\">",
"      Grose C. The many phases of infectious mononucleosis; the spectrum of Epstein-Barr virus infection in children. Pediatr Rev 1985; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/6\">",
"      Horwitz CA, Henle W, Henle G, et al. Clinical and laboratory evaluation of infants and children with Epstein-Barr virus-induced infectious mononucleosis: report of 32 patients (aged 10-48 months). Blood 1981; 57:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/7\">",
"      Tamaki H, Beaulieu BL, Somasundaran M, Sullivan JL. Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children. J Infect Dis 1995; 172:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/8\">",
"      Fleisher G, Bologonese R. Epstein-Barr virus infections in pregnancy: a prospective study. J Pediatr 1984; 104:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/9\">",
"      Goldberg GN, Fulginiti VA, Ray CG, et al. In utero Epstein-Barr virus (infectious mononucleosis) infection. JAMA 1981; 246:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/10\">",
"      Chang RS, Seto DS. Perinatal infection by Epstein-Barr virus. Lancet 1979; 2:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/11\">",
"      Hudson LB, Perlman SE. Necrotizing genital ulcerations in a premenarcheal female with mononucleosis. Obstet Gynecol 1998; 92:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/12\">",
"      Tselis A, Duman R, Storch GA, Lisak RP. Epstein-Barr virus encephalomyelitis diagnosed by polymerase chain reaction: detection of the genome in the CSF. Neurology 1997; 48:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/13\">",
"      Haverkos HW, Amsel Z, Drotman DP. Adverse virus-drug interactions. Rev Infect Dis 1991; 13:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/14\">",
"      Triantos D, Porter SR, Scully C, Teo CG. Oral hairy leukoplakia: clinicopathologic features, pathogenesis, diagnosis, and clinical significance. Clin Infect Dis 1997; 25:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/15\">",
"      Epstein JB, Sherlock CH, Greenspan JS. Hairy leukoplakia-like lesions following bone-marrow transplantation. AIDS 1991; 5:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/16\">",
"      Greenspan D, Canchola AJ, MacPhail LA, et al. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001; 357:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/17\">",
"      Birnbaum W, Hodgson TA, Reichart PA, et al. Prognostic significance of HIV-associated oral lesions and their relation to therapy. Oral Dis 2002; 8 Suppl 2:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/18\">",
"      Walling DM, Etienne W, Ray AJ, et al. Persistence and transition of Epstein-Barr virus genotypes in the pathogenesis of oral hairy leukoplakia. J Infect Dis 2004; 190:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/19\">",
"      Aldrete JS. Spontaneous rupture of the spleen in patients with infectious mononucleosis. Mayo Clin Proc 1992; 67:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/20\">",
"      van Hal S, Senanayake S, Hardiman R. Splenic infarction due to transient antiphospholipid antibodies induced by acute Epstein-Barr virus infection. J Clin Virol 2005; 32:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/21\">",
"      Asgari MM, Begos DG. Spontaneous splenic rupture in infectious mononucleosis: a review. Yale J Biol Med 1997; 70:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/22\">",
"      Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/23\">",
"      Sullivan JL, Woda BA, Herrod HG, et al. Epstein-Barr virus-associated hemophagocytic syndrome: virological and immunopathological studies. Blood 1985; 65:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/24\">",
"      Guinee D Jr, Jaffe E, Kingma D, et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 1994; 18:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/25\">",
"      Myers JL, Kurtin PJ, Katzenstein AL, et al. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol 1995; 19:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/26\">",
"      Haque AK, Myers JL, Hudnall SD, et al. Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: lesions with Epstein-Barr virus infection. Mod Pathol 1998; 11:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/27\">",
"      Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 1979; 43:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/28\">",
"      Fauci AS, Haynes BF, Costa J, et al. Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med 1982; 306:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/29\">",
"      Sordillo PP, Epremian B, Koziner B, et al. Lymphomatoid granulomatosis: an analysis of clinical and immunologic characteristics. Cancer 1982; 49:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/30\">",
"      Wilson WH, Kingma DW, Raffeld M, et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 1996; 87:4531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/31\">",
"      Nagy N, Klein E. Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and promotes lymphoma development. Immunol Lett 2010; 130:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/32\">",
"      Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/33\">",
"      Capello D, Cerri M, Muti G, et al. Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. Hematol Oncol 2006; 24:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/34\">",
"      BURKITT D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/35\">",
"      Donati D, Espmark E, Kironde F, et al. Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis 2006; 193:971.",
"     </a>",
"    </li>",
"    <li>",
"     Miller G. Epstein-Barr virus: Biology, Pathogenesis, and Medical Aspects. In: Virology, Second Edition, Fields BN, Knipe DM (Eds), Raven Press, New York 1990. Vol 2, p.1921.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/37\">",
"      Ziegler JL. Burkitt's lymphoma. N Engl J Med 1981; 305:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/38\">",
"      Brown NA, Liu CR, Wang YF, Garcia CR. B-cell lymphoproliferation and lymphomagenesis are associated with clonotypic intracellular terminal regions of the Epstein-Barr virus. J Virol 1988; 62:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/39\">",
"      Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/40\">",
"      Neri A, Barriga F, Inghirami G, et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991; 77:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/41\">",
"      Rooney CM, Gregory CD, Rowe M, et al. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J Natl Cancer Inst 1986; 77:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/42\">",
"      Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med 1988; 167:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/43\">",
"      Billaud M, Rousset F, Calender A, et al. Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus. Blood 1990; 75:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/44\">",
"      Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007; 38:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/45\">",
"      Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/46\">",
"      Masucci MG, Torsteindottir S, Colombani J, et al. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A 1987; 84:4567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/47\">",
"      BURKITT D. A children's cancer dependent on climatic factors. Nature 1962; 194:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/48\">",
"      Njie R, Bell AI, Jia H, et al. The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis 2009; 199:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/49\">",
"      Mbulaiteye SM, Walters M, Engels EA, et al. High levels of Epstein-Barr virus DNA in saliva and peripheral blood from Ugandan mother-child pairs. J Infect Dis 2006; 193:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/50\">",
"      Moormann AM, Chelimo K, Sumba PO, et al. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 2007; 195:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/51\">",
"      Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst 1993; 85:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/52\">",
"      Cot&eacute; TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/53\">",
"      Shibata D, Weiss LM, Hernandez AM, et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood 1993; 81:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/54\">",
"      Ometto L, Menin C, Masiero S, et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997; 90:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/55\">",
"      Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med 1986; 314:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/56\">",
"      Kersten MJ, Klein MR, Holwerda AM, et al. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest 1997; 99:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/57\">",
"      Pluda JM, Yarchoan R, Jaffe ES, et al. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/58\">",
"      Chadwick EG, Connor EJ, Hanson IC, et al. Tumors of smooth-muscle origin in HIV-infected children. JAMA 1990; 263:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/59\">",
"      McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995; 332:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/60\">",
"      Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995; 332:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/61\">",
"      Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987; 129:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/62\">",
"      Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991; 337:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/63\">",
"      M&eacute;nard F, Besson C, Rinc&eacute; P, et al. Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis 2008; 47:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/64\">",
"      Chang KL, Alb&uacute;jar PF, Chen YY, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993; 81:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/65\">",
"      Kusuda M, Toriyama K, Kamidigo NO, Itakura H. A comparison of epidemiologic, histologic, and virologic studies on Hodgkin's disease in western Kenya and Nagasaki, Japan. Am J Trop Med Hyg 1998; 59:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/66\">",
"      Razzouk BI, Gan YJ, Mendon&ccedil;a C, et al. Epstein-Barr virus in pediatric Hodgkin disease: age and histiotype are more predictive than geographic region. Med Pediatr Oncol 1997; 28:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/67\">",
"      Sixbey JW, Shirley P, Chesney PJ, et al. Detection of a second widespread strain of Epstein-Barr virus. Lancet 1989; 2:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/68\">",
"      Gledhill S, Gallagher A, Jones DB, et al. Viral involvement in Hodgkin's disease: detection of clonal type A Epstein-Barr virus genomes in tumour samples. Br J Cancer 1991; 64:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/69\">",
"      Boyle MJ, Sewell WA, Sculley TB, et al. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood 1991; 78:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/70\">",
"      Young LS, Yao QY, Rooney CM, et al. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol 1987; 68 ( Pt 11):2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/71\">",
"      Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993; 177:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/72\">",
"      Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/73\">",
"      Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978; 4:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/74\">",
"      Andersson-Anvret M, Forsby N, Klein G, Henle W. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer 1977; 20:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/75\">",
"      Lo S, Ho WK, Wei WI. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong. Arch Otolaryngol Head Neck Surg 2004; 130:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/76\">",
"      Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/77\">",
"      Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/78\">",
"      Busson P, McCoy R, Sadler R, et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 1992; 66:3257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/79\">",
"      Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/80\">",
"      Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995; 85:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/81\">",
"      Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 1988; 318:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/82\">",
"      Chen CL, Sadler RH, Walling DM, et al. Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 1993; 67:6303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/83\">",
"      Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000; 96:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/84\">",
"      Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/85\">",
"      Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/86\">",
"      Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/87\">",
"      Emile JF, Boulland ML, Haioun C, et al. CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996; 87:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/88\">",
"      Tynell E, Aurelius E, Brandell A, et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis 1996; 174:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/89\">",
"      Brandfonbrener A, Epstein A, Wu S, Phair J. Corticosteroid therapy in Epstein-Barr virus infection. Effect on lymphocyte class, subset, and response to early antigen. Arch Intern Med 1986; 146:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/90\">",
"      van der Horst C, Joncas J, Ahronheim G, et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis 1991; 164:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/91\">",
"      Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis 1999; 31:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/92\">",
"      Thorley-Lawson DA, Poodry CA. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol 1982; 43:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/93\">",
"      North JR, Morgan AJ, Thompson JL, Epstein MA. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A 1982; 79:7504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/55/14202/abstract/94\">",
"      Epstein MA, Morgan AJ, Finerty S, et al. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985; 318:287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8283 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-9A7ECFAA8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14202=[""].join("\n");
var outline_f13_55_14202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2004981\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2004940\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2004947\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2005083\">",
"      Acute infectious mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2005184\">",
"      Primary EBV infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Congenital and perinatal infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13966774\">",
"      Chronic EBV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Oral hairy leukoplakia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Splenic rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - X-linked lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Posttransplant lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Effect of coinfection with malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Malignancies and HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nasal/nasal type angiocentric lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Antiviral treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Active immunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2004981\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8283\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8283|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/24/1410\" title=\"picture 1\">",
"      Atypical lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/9/34961\" title=\"picture 2\">",
"      Hairy leukoplakia in HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/30/17890\" title=\"picture 3\">",
"      Hemophagocytic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29529?source=related_link\">",
"      Overview of the pathobiology of the non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/11/176?source=related_link\">",
"      Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=related_link\">",
"      The role of Epstein-Barr virus in Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33384?source=related_link\">",
"      X-linked lymphoproliferative disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_55_14203="Parameters during treatment";
var content_f13_55_14203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parameters for monitoring organ system function in patients with sepsis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory system",
"       </td>",
"       <td>",
"        PaO2/FiO2 ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal system",
"       </td>",
"       <td>",
"        Urine output and serum creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematologic system",
"       </td>",
"       <td>",
"        Platelet count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td>",
"        Glasgow coma score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatobiliary system",
"       </td>",
"       <td>",
"        Serum bilirubin and liver enzymes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular system",
"       </td>",
"       <td>",
"        Blood pressure, arterial lactate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal system",
"       </td>",
"       <td>",
"        Gastric intramucosal pH (pHi), ileus, blood in nasogastric aspirate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14203=[""].join("\n");
var outline_f13_55_14203=null;
var title_f13_55_14204="CSF analysis in CNS infections";
var content_f13_55_14204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cerebrospinal fluid analysis in central nervous system infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Glucose (mg/dL)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Protein (mg/dL)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Total white blood cell count (cells/microL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;10",
"        <sup>",
"         *",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-45",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        &gt;250",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        50-250",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        &gt;1000",
"       </td>",
"       <td class=\"subtitle2\">",
"        100-1000",
"       </td>",
"       <td class=\"subtitle2\">",
"        5-100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        More common",
"       </td>",
"       <td>",
"        Bacterial meningitis",
"       </td>",
"       <td>",
"        Bacterial meningitis",
"       </td>",
"       <td>",
"        Bacterial meningitis",
"       </td>",
"       <td>",
"        <p>",
"         Viral meningitis",
"        </p>",
"        <p>",
"         Lyme disease",
"        </p>",
"        <p>",
"         Neurosyphilis",
"        </p>",
"       </td>",
"       <td>",
"        Bacterial meningitis",
"       </td>",
"       <td>",
"        <p>",
"         Bacterial or viral meningitis",
"        </p>",
"        <p>",
"         TB meningitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Early bacterial meningitis",
"        </p>",
"        <p>",
"         Viral meningitis",
"        </p>",
"        <p>",
"         Neurosyphilis",
"        </p>",
"        <p>",
"         TB meningitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less common",
"       </td>",
"       <td>",
"        <p>",
"         TB meningitis",
"        </p>",
"        <p>",
"         Fungal meningitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Neurosyphilis",
"        </p>",
"        <p>",
"         Some viral infections (such as mumps and LCMV)",
"        </p>",
"       </td>",
"       <td>",
"        TB meningitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Some cases of mumps and LCMV",
"       </td>",
"       <td>",
"        Encephalitis",
"       </td>",
"       <td>",
"        Encephalitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LCMV: lymphocytic choriomeningitis virus; TB: tuberculosis.",
"     <br>",
"      * &lt;0.6 mmol/L",
"      <br>",
"       &bull; 0.6-2.5 mmol/L",
"       <br>",
"        &Delta; &gt;2.5 g/L",
"        <br>",
"         &loz; 0.5-2.5 g/L",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14204=[""].join("\n");
var outline_f13_55_14204=null;
var title_f13_55_14205="Adverse drug effects in HF";
var content_f13_55_14205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs associated with increased risk of adverse effects in patients with heart failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug/drug class",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adverse effect(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Anti-inflammatory medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Glucocorticoids",
"      </td>",
"      <td>",
"       Sodium retention (particularly with fludrocortisone, hydrocortisone)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       NSAIDs&bull;",
"      </td>",
"      <td>",
"       Sodium retention and peripheral vasocontriction; blunted response to diuretics and angiotensin converting enzyme inhibitors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Cardiovascular medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Class I antiarrhythmic agents*&bull;",
"      </td>",
"      <td>",
"       Negative inotropy; proarrhythmia; increased mortality with IA and IC agents in post-MI trials",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Class III antiarrhythmic agents (included sotalol and ibutalide)*&bull;",
"      </td>",
"      <td>",
"       Proarrhythmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Calcium channel blockers (other than amlodipine or felodipine)*&bull;",
"      </td>",
"      <td>",
"       Negative inotropy; neurohumoral activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Minoxidil*&bull;",
"      </td>",
"      <td>",
"       Sodium retention; neurohumoral activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Diabetes medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Metformin",
"      </td>",
"      <td>",
"       Lactic acidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Thiazolidinediones&bull;",
"      </td>",
"      <td>",
"       Sodium retention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Phosphdiesterase inhibitors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anagrelide",
"      </td>",
"      <td>",
"       Palpitations; tachycardia; sodium retention; induction or exacerbation of HF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cilostazol",
"      </td>",
"      <td>",
"       Ventricular tachyarrhythmias",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Neurologic and psychiatric medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Amphetamines*&bull;",
"      </td>",
"      <td>",
"       Sympathetic agonist activity; hypertension; tachycardia; tachyarrhythmias",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Carbamazepine",
"      </td>",
"      <td>",
"       Negative inotropic effect; bradyarrhythmias",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clozapine",
"      </td>",
"      <td>",
"       Development of myocarditis and cardiomyopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ergot alkaloids (ergotamine, dihydroergotamine)",
"      </td>",
"      <td>",
"       Sympathetic agonist activity; valve fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pergolide (not available in the US)",
"      </td>",
"      <td>",
"       Valve fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tricyclic antidepressants",
"      </td>",
"      <td>",
"       Negative inotropic effect; proarrhythmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Miscellaneous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Beta-2 agonists",
"      </td>",
"      <td>",
"       Sympathetic agonist activity; tachyarrhythmias; hypokalemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Itraconazole",
"      </td>",
"      <td>",
"       Negative inotropic effect; also can increase serum digoxin concentrations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Licorice",
"      </td>",
"      <td>",
"       Mineralocorticoid excess: sodium retention and hypokalemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sodium-containing preparations (eg, Fleet PhosPho soda)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sodium load QT-prolonging drugs (eg, haloperidol, erythromycin)",
"      </td>",
"      <td>",
"       Proarrhythmia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSAIDs: nonsteroidal anti-inflammatory drugs; SVR: systemic vascular resistance; HF: heart failure.",
"     <br>",
"      * Evidence from randomized placebo controlled trials.",
"      <br>",
"       &bull; Increased risk noted in American College of Cardiology/American Heart Association heart failure guidelines (Hunt SA, et al. Circulation 2005; 112:e154.)",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from Amabile CM, Spencer AP. Arch Intern Med 2004; 164:709.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14205=[""].join("\n");
var outline_f13_55_14205=null;
var title_f13_55_14206="AASLD liver biopsy";
var content_f13_55_14206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Association for the Study of Liver Diseases (AASLD) liver biopsy recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Focal disease and mass lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver biopsy should be considered in patients in whom diagnosis is in question, and when knowledge of a specific diagnosis is likely to alter the management plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver histology is an important adjunct in the management of patients with known liver disease, particularly in situations where (prognostic) information about fibrosis stage may guide subsequent treatment; the decision to perform liver biopsy in these situations should be closely tied to consideration of the risks and benefits of the procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Technical issues, contraindications, and complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior to performance of liver biopsy, patients should be educated about their liver disease and about investigations other than liver biopsy (if any) that may also provide diagnostic and prognostic information.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior to performance of liver biopsy, patients must be carefully informed about the procedure itself including alternatives (as above), risks, benefits, and limitations; written informed consent should be obtained.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Management of medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiplatelet medications should be discontinued several to 10 days before liver biopsy, although there is uncertainty surrounding the need for their discontinuation. Management of specific compounds should be handled on a case-by-case basis, taking into account their clinical indications, as well as the potential bleeding risk associated with their use in the setting of liver biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticoagulant medications should be discontinued prior to liver biopsy. Warfarin should generally be discontinued at least five days prior to liver biopsy. Heparin and related products should be discontinued 12 to 24 hours prior to biopsy. In all patients, the risk of discontinuing anticoagulant medications must be weighed against the (potential) risk of bleeding during/after liver biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiplatelet therapy may be restarted 48 to 72 hours after liver biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin may be restarted the day following liver biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Liver biopsy procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Performance of liver biopsy requires an adequate sized and dedicated physical space suitable for focused physician effort as well as safe patient recovery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The use of sedation, preferably light sedation, is safe and does not lead to increased procedural risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vital signs must be frequently monitored (at least every 15 minutes for the first hour) after liver biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The recommended observation time after biopsy is between two to four hours and will vary depending on local expertise and practice.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound guidance with marking of the optimal biopsy site performed immediately preceding biopsy, by the individual performing the biopsy, is preferred, though not mandatory, because it likely reduces the risk of complications from liver biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous liver biopsy with or without image guidance is appropriate only in cooperative patients, and this technique should not be utilized in uncooperative patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncooperative patients who require liver biopsy should undergo the procedure under general anesthesia or via the transvenous route.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with clinically evident ascites requiring a liver biopsy, a transvenous approach is generally recommended, although percutaneous biopsy (after removal of ascites) or laparoscopic biopsy are acceptable alternatives.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients who require liver biopsy and who have a large vascular lesion identified on imaging should undergo the procedure using real-time image guidance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The decision to perform liver biopsy in the setting of abnormal laboratory parameters of hemostasis should continue to be reached as the result of local practice(s) and consideration of the risks and benefits of liver biopsy because there is no specific PT-INR and/or platelet count cutoff at or above which potentially adverse bleeding can be reliably predicted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Those performing liver biopsy must be cognizant of multiple potential complications (including death) that may occur after liver biopsy and discuss these appropriately with their patients beforehand.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet transfusion should be considered when levels are less than 50,000 to 60,000/mL (this applies whether one is attempting biopsy transcutaneously or transvenously).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The use of prophylactic or rescue strategies such as plasma, fibrinolysis inhibitors, or recombinant factors should be considered in specific situations, although their effectiveness remains to be established.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with renal failure or on hemodialysis, desmopressin (DDAVP) may be considered, although its use appears to be unnecessary in patients on stable dialysis regimens.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients on chronic hemodialysis should be well dialyzed prior to liver biopsy, and heparin should be avoided if at all possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Radiological considerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Image-guided liver biopsy is recommended in certain clinical situations including in patients with known intrahepatic lesions (real-time imaging is strongly preferred) and in those with previous intraabdominal surgery who may have adhesions. Image-guided liver biopsy should also be considered in the following situations: patients with small livers that are difficult to percuss, obese patients, and patients with clinically evident ascites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pathological considerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Because diagnosis, grading, and staging of nonneoplastic, diffuse parenchymal liver disease is dependent on an adequate sized biopsy, a biopsy of at least 2 to 3 cm in length and 16-gauge in caliber is recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        It is recommended that if applicable, the presence of fewer than 11 complete portal tracts be noted in the pathology report, with recognition that diagnosis, grading, and staging may be incorrect due to an insufficient sample size.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If cirrhosis is suspected, a cutting rather than a suction needle is recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In clinical practice, use of a simple (eg, Metavir or Batts-Ludwig) rather than complex (eg, Ishak) scoring system is recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noninvasive alternatives to liver biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver biopsy is currently a fundamentally important tool in the management of patients with liver disease, important for diagnosis as well as staging of liver disease and its use is recommended until clearly superior methodologies are developed and validated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Training for liver biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specific training for liver biopsy is essential and is recommended for those who perform it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver biopsy should be taught to trainees by experts, highly experienced in the practice of liver biopsy and management of its potential complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Although the number of biopsies required to become adequately trained is unknown, it is recommended that operators perform at least 40 biopsies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Training in percutaneous liver biopsy should include specific training in ultrasound interpretation of fundamental liver anatomy and other landmarks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Image-guided liver biopsy should be taught to trainees by experts who themselves have adequate training and experience with the technique.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49:1017.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14206=[""].join("\n");
var outline_f13_55_14206=null;
var title_f13_55_14207="Reciprocal translocations";
var content_f13_55_14207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Mechanism of reciprocal translocations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 765px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nonhomologous chromosomes exchange parts without loss of genetic content. When meiotic division occurs, the normal and translocated chromosomes can only pair by forming a quadrivalent structure. The resulting segregation products include a normal chromosome complement, a balanced rearrangement, and four unbalanced products. The unbalanced products can be subdivided into two products with correct and two products with incorrect centromere segregation. The latter event is rare and associated with decreased viability.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_55_14207=[""].join("\n");
var outline_f13_55_14207=null;
